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Zusammenfassung 
Synthese neuer krebshemmender Substanzen mit tetrazyklischer Grund-
struktur 
Theerachart Leepasert, Universität Wien Betreuer: Univ.-Prof. Dr. Helmut Spreitzer 
 
Dissertation zur Erlangung des akademischen Grades Doktor der Naturwissenschaften                    
Im Zuge dieser Arbeit sollten drei Serien von DNA-interkalierenden Verbindungen syntheti-
siert sowie ein neuer synthetischer Zugang zu Ellipticin (49) geschaffen werden. In der ersten 
Serie (107-109, 114, 120, 124) wurde eine Reihe Pyridin-anellierter Carbazole durch Anlage-
rung verschiedener Aminoalkyl- und Hydroxyalkylsulfidseitenketten an den Stickstoff des 
Pyrrolringes hergestellt. Sämtliche Verbindungen zeigten starke Zytotoxizität gegen 
NClH460 Zelllinien. Außerdem wiesen die Verbindungen 109, 114 und 124 moderate Zyto-
toxizität gegen SKOV3 Zelllinien auf. Der zweiten Serie lag die Reaktion von 6,7-Dichlor-
5,8-isochinolindion oder 6,7-Dichlor-5,8-Chinazolindion und als zweitem Edukt substituier-
tes 2-Aminopyridin oder unsubstituiertes 2-Aminopyridin zugrunde, die zu den Verbindun-
gen 128(a,b), 134(a,b), 136a und 143a führten. Zusätzlich konnte an Substanz 128a eine 
Aminoseitenkette eingeführt werden, wodurch die Darstellung von Verbindung 138b ermög-
licht wurde. Die dritte Serie wurde durch nukleophile aromatische Substitution an 
Anthrapyrazol mit verschiedenen Aminen realisiert, daraus resultierten die Verbindungen 
155, 157, 159, 161, 163 und 165. Die letzten beiden Serien werden derzeit noch auf ihre 
krebshemmende zytostatische Wirkung getestet. Für Ellipticin sollte eine neue, besonders 
kurze Synthese via Buchwald-Hartwig-Kopplung und anschließender Ringschlussmethode 
entwickelt werden. Dies konnte zwar nicht realisiert werden, die Synthese der Schlüsselver-
bindung 169 wurde jedoch erfolgreich auf drei Schritte verkürzt, was zumindest einer Opti-
mierung der in den letzten Publikationen diskutierten Syntheseroute entspricht. 
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107: R = -(CH2)2S(CH2)2OH  108: R = -(CH2)2-N-morphorine        
109: R = -(CH2)2-N-pyrrolidine  114: R = -(CH2)2-N-oxazolidine 
120: R = -(CH2)2-N-1-methylpiperazine 124: R = -(CH2)2NMe(CH2)2OH       
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128a:  X = N, Y = C, Z = C ; R1 = Cl, R2 = H             128b:  X = C, Y = N, Z = C ; R1 = Cl, R2 = H    
134a:  X = N, Y = C, Z = C ; R1 = Br, R2 = H       134b:  X = C, Y = N, Z = C ; R1 = Br, R2 = H 
136a:  X = N, Y = C, Z = C ; R1 = NO2, R2 = H    138b:    X = N, Y = C, Z = C ; R1 = Cl, R2 = -NMe(CH2)2NMe2                 
143a:  X = N, Y = C, Z = N ; R1 = H, R2 = H 
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155 : R  =  -(CH 2)3SCH 3
157 : R  =  
159 : R  =
161 : R  =
163 : R  =  
165 : R  =
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ABSTRACT 
 
SYNTHESIS OF NEW ANTICANCER COMPOUNDS WITH  A TETRACYCLIC 
NUCLEUS 
 
Theerachart Leepasert, University of Vienna Thesis Advisor: Prof. Helmut Spreitzer 
A Thesis submitted in partial fulfillment of the requirement for the degree of doctor of science 
 
 Three series of DNA intercalating agents were modified and synthesized and a novel 
synthetic approach to ellipticine (49) was investigated. In the first series (107-109, 114, 120, 
124), pyridocarbazoles have been assembled by attachment of various amino alkyl and 
hydroxy alkyl sulfide side chains on the nitrogen atom of pyrrole ring. All of them showed 
strong cytotoxicity against NClH460 cell lines. Moreover 109, 114, and 124 presented mode-
rate cytotoxicity against SKOV3 cell lines. The second series was the reaction between 6,7-
dichloro-5,8-isoquinolinedione/6,7-dichloro-5,8-quinazolinedione and substituted 2-
aminopyridine/2-aminopyridine, yielding to new tetracyclic compounds 128(a,b), 134(a,b), 
136a, and 143a. Moreover, 128a could be introduced amine side chain at ring A to provide 
138b. The third series was synthesized by nucleophilic aromatic substitution of 
anthrapyrazole (153) with various amines, leading to 155, 157, 159, 161, 163, and 165.  Both 
the second and the third series are being investigated concerning anticancer activity. Finally, 
Buchwald-Hartwig coupling and ring closure method could not be employed for the aspired 
shortest route to ellipticine. However, key intermediate 169 could be successfully synthesized 
in three steps, shorter than in recent reports described. 
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ABBREVIATIONS 
 
Ac2O   acetic anhydride 
AlCl3   aluminium chloride 
bp   boiling point 
br   broad 
[BF4][HPtBu3] tri(tert-butyl)phosphonium tetrafluoroborate 
Bu4NF   tetrabutylammonium fluoride 
CeCl3.7H2O  cerium trichloride heptahydrate 
CDCl3   deuterochloroform 
CH2Cl2  dichloromethane 
CO2   carbondioxide 
d   doublet 
dd   double doublet 
DHFR   dihydrofolate reductase 
DMF   dimethyl formamide 
DMSO  dimethyl sulfoxide 
EtOAc   ethyl acetate 
EtOH   ethanol 
eV   electron colt 
g   gram 
h   hour (s) 
HCl   hydrochloric acid 
HNO3   nitric acid 
HRMS  high resolution mass spectrometry 
H2SO4   sulfuric acid 
Hz   hertz 
IR   infrared 
J   coupling constant 
K2CO3   potassium carbonate 
KOH   potassium hydroxide 
LDA   lithium diisopropylamide 
LiN[Si(CH3)3]2 lithium-bis(trimethylsilyl)amide 
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m   multiplet 
M   molar 
MeOH   methanol 
mg   milligram 
MHz   megahertz 
min   minute (s) 
mL   milliliter 
mmol   millimole 
m/z   a value of mass divided by charge 
M+   molecular ion 
mp   melting point 
MS   mass spectrometry 
NaH   sodium hydride 
NaOH   sodium hydroxide 
NaOMe  sodium methoxide 
NaOtBu  sodium tertiary butoxide 
Na2SO4  sodium sulfate 
NBS   N-bromosuccinimide 
Ni(PPh3)2Cl  bis[triphenylphosphine]nickel(II) 
NMR   nuclear magnetic resonance 
Pd(OAc)2  palladium(II)acetate 
Ph   phenyl 
PhSO2Cl  benzenesulfonylchloride 
ppm   part per million 
p-TsOH.H2O  para toluene sulfonic acid monohydrate 
pyr   pyridine 
RT   room temperature 
s   singlet 
SiO2   silica gel 
SOCl2   thionyl chloride 
t   triplet 
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TLC   thin layer chromatography 
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CHAPTER I 
 
INTRODUCTION 
 
 Cancer is a collective term used for a group of diseases that are characterized by the 
loss of control of the growth, division, and spread to other regions of the body through a pro-
cess known as metastasis, which is the cause of 90% of cancer death. Cancer remains one of 
the most difficult diseases to treat and is responsible for 13% of all deaths worldwide, and 
this disease is increasing due to the aging of population in most countries, but especially in 
the developed ones. 
 
1. Principles of cell cycle and cancer        
1.1 The cell cycle  
The cell cycle, or cell-division cycle, is the series of events that take place in a cell 
leading to its division and duplication (replication). In cells without a nucleus (prokaryotes), 
the cell cycle occurs via a process termed binary fission. In cells with a nucleus (eukaryotes), 
the cell cycle can be divided in two brief periods: interphase during which the cell grows, 
accumulating nutrients needed for mitosis and duplicating its DNA and the mitosis (M) pha-
se, during which the cell splits itself into two distinct cells, often called "daughter cells". The 
cell-division cycle is a vital process where a single-celled fertilized egg develops into a 
mature organism, as well as the process where hair, skin, blood cells, and some internal or-
gans are renewed. 
 
The cell cycle consists of four distinct phases: G1 phase, S phase (synthesis), G2 phase 
(collectively known as interphase) and M phase (mitosis). M phase is itself composed of two 
tightly coupled processes: mitosis where the cell's chromosomes are divided into the two 
daughter cells, and cytokinesis where the cell's cytoplasm divides forming distinct cells. 
Activation of each phase is dependent on the proper progression and completion of the 
previous one. Cells that have temporarily or reversibly stopped dividing are said to have 
entered a state of quiescence called G0 phase [1]. 
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Figure 1. The eukaryotic cell cycle 
 
G1 phase : This phase is marked by synthesis of various enzymes that are required in S phase    
mainly those needed for DNA replication. 
 
S phase : During this phase, the amount of DNA in the cell has effectively doubled, though 
the ploidy for the cell remains the same. Rate of RNA transcription and protein synthesis are 
very low during this phase. 
 
G2 phase : Significant protein synthesis occurs during this phase, mainly involving the 
production of microtubules, which are required during the process of mitosis. 
 
M phase : The M phase has been broken down into several distinct phases. Sequentially 
known as prophase, prometaphase, metaphase, anaphase, and telophase leading to 
cytokinesis. 
 
1.2 Cancer  
Cancer (medical term: malignant neoplasm) is a class of diseases in which a group of 
cells display uncontrolled growth (division beyond the normal limits), invasion (intrusion on 
and destruction of adjacent tissues), and sometimes metastasis (spread to other locations in 
the body via lymph or blood). These three malignant properties of cancers differentiate them 
from benign tumors, which are self-limited, do not invade or metastasize. Most cancers form 
a tumor but some, like leukemia, do not. The branch of medicine concerned with the study, 
diagnosis, treatment, and prevention of cancer is oncology. 
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Genetic abnormalities found in cancer typically affect two general classes of genes. Can-
cer-promoting oncogenes are typically activated in cancer cells, giving those cells new prop-
erties, such as hyperactive growth and division, protection against programmed cell death, 
loss of respect for normal tissue boundaries, and the ability to become established in diverse 
tissue environments. Tumor suppressor genes are then inactivated in cancer cells, resulting in 
the loss of normal functions in those cells, such as accurate DNA replication, control over the 
cell cycle, orientation and adhesion within tissues, and interaction with protective cells of the 
immune system. 
2. A brief account of the role of chemistry in cancer chemotherapy 
 
Chemistry has had varying roles in the discovery and development of anticancer drugs 
since the beginning of cancer therapies [2]. In its early history, chemical modification of sul-
fur mustard gas led to the serendipitous discovery of the still clinically useful nitrogen 
mustards. Since those years, synthetic chemistry has been extensively used to modify drug 
leads, especially those of natural origin, and to solve the problem of the often scarce supply 
of natural products by developing semisynthetic or synthetic strategies.  
 
Since the 1950s, chemistry has also generated many antitumor drug leads through in vitro 
screening programs promoted by the National Cancer Institute (NCI) in the United States by 
using a range of cancer cell lines. In this early period transplantable rodent tumor models 
characterized by a high growth rate were used for in vivo screening. Later on, human tumor 
xenograft, based on transplantation of human tumor tissue into immune-tolerant animals, 
became also important tools for selecting drugs because the xenografts models allowed to 
stimulate a chemotherapeutic effect under conditions closer to man. In the late seventies and 
early eighties, the role of chemotherapy was extended to preoperative and postoperative 
adjuvants, radiosensitizers to enhance radiation effects and supportive therapy to increase the 
tolerance of the organism toward toxicity [3].  
 
Cancer therapy is based on surgery and radiotherapy, which are, when possible, rather 
successful regional interventions, and on systemic chemotherapy. Approximately half of the 
cancer patients are not cured by these treatments and obtain only a prolonged survival or no 
benefit at all. The aim of most cancer chemotherapeutic drugs currently in clinical use is to 
kill malignant tumor cells by inhibiting some of the mechanism implied in cellular division. 
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Hence, the antitumor compounds developed through this approach are cytostatic or cytotoxic. 
However, the knowledge of tumor biology has exploded during the past decades and this may 
pave the way for more active, targeted cancer therapies. 
 
2.1 Antimetabolites 
 
 Antimetabolites can be defined as analogs of naturally occurring compounds that 
interfere  with their formation, thus inhibiting essential metabolic routes. Although the enzy-
mes inhibited by antimetabolites are also present in normal cells, some selectivity toward 
cancer cell is possible due to their faster division rates. Most antimetabolites interfere with 
nucleic acid synthesis and sometimes with RNA. Specific interference with the de novo 
nucleic acid pathway in cancer cell is probably not possible because tumor and normal cell 
use the same biosynthetic pathways. Nevertheless, some antimetabolites are remarkably 
effective against some human cancers and are still basic cancer therapeutics [4-5]. 
 
  One of the most widely prescribed class of antimetabolites is 5-fluorouracil (1) (5-
FU), it is used in the treatment of cancer of the aerodigestive tract, breast, head and neck and 
especially in colorectal cancer in combination therapies with oxaliplatin and irinotecan. 
Administered as a cream, it is also useful for the treatment of some skin cancers. 5-FU is a 
prodrug that enters the cell using the same facilitated transport mechanism as uracil and is 
activated to 5-fluoro-2’-deoxyuridine-monophosphate and more metabolites to active species 
5-fluoro-2’-deoxyuridine-triphosphate, which eventually inhibit DNA synthesis. 
 
HN
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H
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O
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1: 5-Fluorouracil 
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 5-FU requires intravenous administration and a number of oral prodrugs have been 
designed to avoid this limitation. One of them is ftorafur (2) which is completely absorbed in 
the gastrointestinal tract and metabolized to 5-FU. However it has shown cardiac toxicities. 
Thus, capecitabine (3) is a multiple prodrug, designed to be activated specifically with tumor 
cell. This compound has shown higher activity and less toxicity than ftorafur. 
NH
O
ON
O
F
NH
HN
ON
O
OHOH
CH3
F
O
O
nC5H11
 
  2: Ftorafur     3: Capecitabine   
 
2.1.1 Inhibitors of dihydrofolate reductase (DHFR) 
 
 Folic acid and its metabolites are coenzymes of many essential biochemical transfor-
mations. Most importantly, they are involved in the transformation of one carbon unit in the 
DNA synthesis (thymidylic acid and purine nucleotides). Folate-dependent enzymes are 
obvious targets for cancer chemotherapy but until 1980 only DHFR was exploited in this 
regard. The most potent inhibitors of DHFR are folic acid analogs that differ from the natural 
ligand by carrying a 2,4-diaminopyridine unit, as shown by aminopterine (4), methotrexate 
(5), edatrexate (6) and 10-propagyl-10-deazaaminopterine (PDX) (7) which is under clinical 
investigation. The inhibitors where the side chain ends in a glutamic acid residue, like folic 
acid, are known as classical antifolates [6]. 
N
N N
N
NH2
H2N
N
R
N
H
O CO2H
CO2H
 
 
  4: R = H; Aminopterine   5: R = CH3; Methotrexate 
  6: R = CH2CH3; Edatrexate   7: R = CH2C≡CH; PDX 
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2.2 Anticancer drugs that inhibit hormone action 
 
 Hormones, and in particular steroid hormones, are the main determinants in induction 
and growth of several types of tumor or cancer and for this reason the search for antihormo-
nes has been one of the mainstays of cancer chemotherapy. Thus, compounds acting on 
estrogen and androgen receptors (ARs) are involved in the treatment of breast and prostatic 
cancers. 
 
2.2.1 Nonsteroidal antiestrogen (SERMs) 
 
 The first discovered antiestrogen was clomiphene (8), but its development for the 
treatment for advanced breast cancer was discontinued because of concerns about potential 
side effects [7]. In 1974, tamoxifene (9) was the first antiestrogen to be approved for the 
treatment of advanced breast cancer. Tamoxifene also binds with high affinity to other tar-
gets, such as the microsomal antiestrogen binding site, protein kinease C, calmodulin-
dependent enzymes and acyl coenzyme A. 
 
 Tamoxifene has estrogenic agonist effects on other tissues such as bone and 
endometrium due to the nonspecific activation of their estrogen receptors (ERs). For this rea-
son, several antiestrogen compounds, known as SERMs, have been developed that have a 
reduced agonist profile on breast. Some of these compounds belong to the triphenylethylene 
family, including toremifene (10), droloxifene (11) and idoxifene (12). 
 
Cl
O
N
O
N
R
 
  8: Clomiphene     9: R = H; Tamoxifene 
                  10: R = Cl; Toremifene 
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O
N
HO
O
N
I
 
  11: Droloxifene                    12: Idoxifene 
 
2.2.2 Steroidal antiestrogens 
 
Structurally, the main family of selective estrogen antagonists are steroids carrying a 
long lipophilic chain at C-6, represented by fulvestrant (ICI-182786) (13) which has been 
approved for the treatment of postmenopausal women with hormone-sensitive advance breast 
cancer following prior endocrine therapy. 
CH3
OH
HO
S
O F
F
F
F
F
 
13: Fulvestrant 
 
2.2.3 Nonsteroidal aromatase inhibitors 
 
This group of inhibitors comprises structurally varied compounds that are able to bind 
to the active site of aromatase through the coordination of a heterocyclic nitrogen atom, 
usually an imidazole or triazole ring, to the iron atom of the heme group of the enzyme. 
Because of the similarity of aromatase with other essential enzymes of the cytochrome P450 
group, the main problem to be solved is one of selectivity. On the contrary, they have the 
advantage over steroidal inhibitors of not being subject to metabolism by the cytochrome 
enzyme system. The structures of the main drugs belonging to this group are given below. 
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14: Anastrozole           15: Vorozole    16: Letrozole 
 
Nonsteroidal aromatase inhibitors include the triazole derivatives anastrozole (14), 
vorozole (15), and letrozole (16), which are very potent and specific aromatase inhibitors that 
allow almost complete estrogen suppression [8]. 
 
2.2.4 Steroidal aromatase inhibitors 
 
The first member of this class of compounds to be recognized as an aromatase inhibi-
tor was subsequently 1,4-androstadiene-3,17-dione (17). Among other more highly 
unsaturated compounds, the most relevant is the 6-methylene derivative, known as 
exemestane (18) [9]. Exemestane was approved more recently for clinical use in some count-
ries and has the advantages over formestane of being more potent and, specially, of allowing 
oral administration [10]. 
O
CH3
CH2
O
CH3
O
CH3
O
CH3
 
17: 1,4-Androstadiene-3,17-dione    18: Exemestane 
 
2.2.5. Antiandrogens 
 
Androgen antagonists [11] bind to the receptor and prevent binding of the natural ste-
roids, but they do not produce the correct conformational change in the receptor that is essen-
tial to elicit normal changes in gene expression. Cyproterone acetate (19) is a steroidal anti-
androgen that was initially developed as a synthetic gestagen to be used as a contraceptive, 
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but the observation of feminization of the offspring in gestating rats led to its identification as 
a competitive inhibitor of the AR. It is used in prostatic carcinoma, but its side effects of 
gynecomastia and edema, which can be attributed to its analogy with natural gestagens and 
glucocorticoids, respectively, stimulated the search for nonsteroidal compounds with pure 
antiandrogenic action (SARM, selective androgen receptor modulators). 
 
CH3
O
CH3
O
O
CH3
Cl
OH3C
 
19: Cyproterone acetate 
 
 Flutamide (20) was the first nonsteroidal antiandrogen [12]. It does not act on andro-
gen receptors, but it is metabolized by hydroxylation to the active species. This metabolite 
inhibits both androgen uptake and binding of androgens to their receptors in target tissues. 
Other antiandrogens that are in clinical use for the treatment of prostate cancer are 
bicalutamide (21) and nilutamide (22), which have the advantage over flutamide by having a 
longer half-life that allows its administration only once daily. 
 
O2N
F3C N
H
O
O2N
F3C N
H
O
OH
metabolism
 
20: Flutamide             Flutamide active metabolite 
 
O2N
F3C N
H
O
S
HO
O
O
O2N
F3C N
N
H
O
O
F
 
 21: Bicalutamide      22: Nilutamide 
 
2.3 DNA Alkylating Agents 
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 Anticancer drugs that target DNA have been used in clinic for more than 60 years. 
Despite the recent major advances in cancer research, the mechanism by which most 
clinically relevant anticancer drugs kill cells consist of interference with replication, which 
can be succeeded most simply by DNA alkylation. Alkylating agents can be defined as 
compounds capable of covalently binding an alkyl group to a biomolecule. DNA alkylating 
agents interact with resting and proliferating cells in any phase of the cell cycle, but they are 
more cytotoxic during the late G1 and S phases because there is not enough time available to 
repair the damage before DNA synthesis occurs. The main types of DNA alkylating drugs 
have been classified as follows: nitrogen mustards, aziridines (ethyleneimines), methansulfo-
nates, and platinum complexes. 
 
2.3.1 Nitrogen mustards 
 
 Sulfur mustard (23) was used in the World War I for chemical warfare. It is an 
extremely irritant agent. After that, it was realized that this compound could play a role in 
cancer treatment, but after an exploratory study, it was considered as too toxic for normal 
cells, and the nitrogen analog of sulfur mustard know as mechlorethamine (mustine) (24) was 
developed.  It was applied to a lymphosarcoma patient in 1943.  Afterwards, other nitrogen 
mustards for example chloramubucil (25), melphalan (26), bendamustin (27), and uracyl 
mustard (28) [13] were developed for the reason of more activity and less toxicity than 
mustine. 
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  25: Chlorabucil     26: Melphalan 
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  27: Bendamustin     28: Uracyl mustard 
 
 
Because of the relative unreactivity of alkyl chloride as electrophiles, direct attack of 
DNA nucleophilic centers to nitrogen mustard under physiological condition is too slow 
because of therapeutic relevance. The reason why nitrogen mustards have a high reactivity as 
alkylating agents under mild conditions is the anchimeric assistance of the nitrogen atom. As 
a consequence of this the formation of an intramolecular aziridinium cation happens. The 
aziridinium cation is highly reactive because of its positive charge at the leaving group and 
high strain of the three membered ring. Since the most nucleophilic atom in DNA is the N-7 
nitrogen of guanine, the most common species arising from alkylation as illustrated in 
scheme 1. 
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Scheme 1 
 
Another consequence of guanine alkylation is an increase in the electrophilicity of the 
position adjacent or conjugated to the positive charge of N-7, which leads to several 
hydrolytic reactions that alter the DNA structure. Thus, cleavage of the heteroside bond in 
structure (a) although slow [14], induces DNA depurination to give (b).This structure is in 
equilibrium with the open form (c), which has a good leaving group. This arrangement leads 
to an easy elimination process whereby DNA is fragmented to (d) and (e) as shown in 
scheme 2. 
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Because nitrogen mustards are bifunctional alkyating agents, one of their cytotoxicity 
mechanisms is related to the ability of DNA-monoalkyated species (f) to give covalent DNA 
interstrand and intrastrand cross-links (g) or DNA-protein complexes (h) from the 
monoalkyated species (f), leading to disruption of replication or transcription process as 
shown in scheme 3. 
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 Another strategy for the development of site-directed nitrogen mustards can be the 
selective bioactivation of prodrug forms if biochemical differences can be found between a 
tumor and normal tissue. Thus, a report stating that some tumors contain high levels of phos-
phoramidase led to design of prodrug nitrogen mustards, which were expected to be activated 
by phosphoramide enzymatic hydrolysis. This assumption led to the preparation of 
cyclophosphamide (29), first reported in 1958, which has become the main antitumor drug of 
alkylating class, being used to treat lymphomas, leukemias, and often in combination with 
other drugs to treat breast cancer, leukemia, and overian cancer. Ifosfamide (30), a related 
compound, is used to treat testicular cancer. In both compounds the electron-withdrawing 
effect of the P=O bond prevents their activation to aziridinium cation. Finally, the negative 
charge on the phosphoramidate oxygen atom balances the electron-withdrawing effect of the 
P=O group, and allows its activation to an aziridinium cation. Phosphoramide mustard can be 
hydrolyzed to nornitrogen mustard, which is also active (scheme 4). 
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Scheme 4 Bioactivation of cyclophosphamide. 
 
2.3.2 Aziridines 
 
 Since the active species involved in DNA alkylation by nitrogen mustards is an 
aziridinium cation, several aziridine derivatives were also tested as antitumor agents. Early 
studies showed that at least two aziridine units were necessary for good activity. The first 
compounds of this family to be introduced in therapeutics were triethylenemelamine (TEM) 
(31) and thiotepa (32), so called because it is a sulfur analog of triethylenephosphoramide 
(TEPA) (33). 
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 31: TEPA       32: Thiotepa     33: TEM 
 
 
 Other antitumor compounds contain two or three aziridine rings linked to a 
benzoquinone system and can act as DNA bisalkylators and cross-linking agents. They were 
designed to cross the blood-brain barrier because of their high lipophilicity and low 
ionization. Some of them have been used in clinic, as it is in the case of carboquone 
(carbazilquone) (34), diaziquone (AZQ) (35), triaziquone (36), and BZQ (37). AZQ, one of 
the most active compounds, has been studied in a number of clinical trials up to Phase II. In 
case of BZQ and triaziquone also underwent clinical trials [15], but finally, they were 
withdrawn due to their toxicity.  
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2.3.3 Methanesulfonates 
 
 Methanesulfonate is a good leaving group because of the efficient delocalization of 
negative charge between three oxygen atoms. For this reason, several compounds containing 
two methansulfonate groups separated by a polymethylene chain were tested as antitumor 
agents, finding that the optimal activity corresponded to the compound with four carbon 
atoms (busulfan (38) [16]. Other members of this family are piposulfan (39), improsulfan 
(40), hepsulfan (41) and the diepoxide prodrug treosulfan (42). 
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40: R = CH3, Z = NH; Improsufan 
41: R = NH2, Z = CH2; Hepsulfan 
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2.3.4 Platinum complexes 
 
 Cisplatin (43) (CDPP, cis-diaminedichloroplatinum II) provides an excellent example 
of serendipity in the discovery of antitumor drugs. In the course of the study of the effects of 
electric currents on cells, it was discovered that Escherichia coli cells formed long filaments, 
but they did not divide. Further research showed that inhibition of bacterial cell division was 
due to cisplatin, generated from the platinum electrodes and the ammonium chloride present 
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in the media. Because of the very high toxicity of cisplatin, thousands of analogs have been 
prepared in an effort to improve its selectivity and therapeutic index. The renal side effects 
are a great problem and dose-limiting. The causes for the renal side effects are interactions 
with renal components, leading to tubular necrosis of both proximal and distal renal tubules. 
Cisplatin analogs include tetragonal Pt(II) complexes, such as carboplatin (44), oxaliplatin 
(45), nedaplatin (46), ZD-0473 (47), and SKI 2053R (48) [17]. 
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 46: Nedaplatin    47: ZD-0473       48: SKI 2053R 
 
2.4 DNA intercalation and its consequences 
 
 Many anticancer drugs in clinical use (e.g. anthracyclins, mitoxantrone, 
dactinomycin) interact with DNA through intercalation, which can be defined as the process 
by which compounds containing planar aromatic or heteroaromatic ring systems are inserted 
between adjacent base pairs perpendicularly to the axis of helix and without disturbing the 
overall stacking pattern due to Watson-Crick hydrogen bonding. 
 
 The intercalation process starts with the transfer of the intercalating molecule from an 
aqueous environment to the hydrophobic space between two adjacent DNA base pairs. This 
process is thermodynamically favoured because of the positive entropy contribution associa-
ted to disruption of the organized shell of water molecules around the ligand (hydrophobic 
effect) [18]. In order to accommodate the ligand, DNA must undergo a conformational chan-
ge involving an increase in chromophore. The double helix is thereby partially disturbed [19], 
which leads to distortions of the sugar-phosphate backbone and changes in the twist angle 
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between successive base pairs (Figure 2). Once the drug has been sandwiched between the 
DNA base pairs, the stability of the complex is optimized by a number of non-covalent inter-
actions, including van der Waals and π-stacking interactions [20], reduction of coulombic 
repulsion between the DNA phosphate groups associated with the increased distance between 
the bases because of helix unwinding, ionic groups, and hydrogen bonding. 
 
Figure 2 Deformation of DNA by an intercalating agent. 
 
 Ellipticine (49), an alkaloid isolated from the leave of Ochrosia elliptica and other 
Apocymaceae plants, is the prototype of intercalators based on the pyridocarbozole system 
and displays a broad spectrum of anticancer activity [21]. S-16020 (50) is another 
pyridocarbazole derivative, carrying a (dimethylamino)ethylcarboxamide side chain that 
increases its DNA-intercalating ability. This drug is a potent stimulator of topotisomerase II-
mediated DNA cleavage. Despite its close similarity with ellipticine, both compounds show 
little cross-resistance. 
N
N
CH3
CH3H
N
N
CH3CH3
O
H
N
N
HO
 
           49: Ellipticine     50: S-16020 
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Intoplicine (51) is an intercalating compound that can be considered as structurally 
related to the ellipticines. It behaves as a dual topoisomerase I and II poison at cleavage sites 
different to those of other known topoisomerase inhibitors [22]. From spectroscopic results 
two types of DNA complexes have been proposed an accounting for topoisomerase I- and II-
mediated cleavages, involving a ‘deep intercalation mode’ or an ‘outside binding mode’, 
respectively [23]. Because of the high activity of intoplicine in preclinical cancer models, 
original mechanism of action and acceptable toxicity profile, it was further evaluated in 
several Phase I studies [24]. 
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51: Intoplicine 
 
 TAS-103 (52) is a dual topoisomerase I and II inhibitor that has marked efficacy 
against various lung metastatic cancers and a broad antitumor spectrum, and it has reached 
clinical trails for treatment of solid tumors. DNA binding and unwinding assays indicate that 
TAS-103 intercalates in to DNA [25]. 
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52: TAS-103 
 
 Chartreusin (53) and elsamicin A (54) are structurally related antitumor antibiotics 
that were isolated from Streptomyces chartreusis and from an unidentified actinomycete 
strain, respectively. Chartreusin suffers from unfavourable pharmacokinetics (slow oral ab-
sorption and biliar excretion) which prevented its clinical development. Semi-synthetic 
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chartreusin analogs with improved pharmacokinetics have been developed. One of them, 
IST-622 (55), is under Phase II clinical trials for the oral treatment of breast cancer [26]. 
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Naphthalimide derivatives bearing an aminoalkyl side chain such as mitonafide (56) 
and amonafide (57) have shown interesting cytotoxic activity [27], which is due to 
intercalation and topoisomerase II inhibition [28]. Both mitonafide and amonafide have been 
extensively tested in clinical trials but have not been employed in therapeutics, although they 
have been used as leads in the design of bis-intercalators. 
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56: R = NO2; Mitonafide 
57: R = NH2; Amonafide 
 
In effort to increase the binding constant of intercalating compounds, bifunctional or 
even polyfunctional compounds have been designed. Bifunctional intercalators usually 
contain two intercalating two cationic units, separated by a spacer chain that must be long 
enough to allow double intercalation taking into account the neighbour exclusion principle as 
illustrated in figure 3.  
 
Figure 3 Interaction between a bis-intercalator and DNA. 
 
 Elinafide (58) is a bis-intercalator derived from naphthalimide pharmacophore [29] 
that showed antitumor activity and reached Phase I clinical trials, showing anti-neoplastic 
activity in ovarian cancer, breast cancer, and mesothelioma.  
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2.5 Topoisomerases inhibitors 
 
 Topoisomerases are crucial for several DNA functions (e.g. replication and 
transcription). Topoisomerase I breaks a single DNA strand while Topoisomerase II brakes 
both strands and requires ATP for full activity. Drugs that can inhibit the topoisomerases, 
including some of the most widely used anticancer drugs. 
 
2.5.1 Topoisomerase I inhibitor 
 
Topoisomerase I was validated as a target for cancer chemotherapy when it was 
identified as the sole target of camptothecin (59) (CPT). This compound was isolated in 1966 
from the Chinese tree Camptotheca acuminata and its therapeutic development was initially 
limited by its poor solubility and unacceptable toxicity. The identification of topoisomerase I 
as its target prompted the search for water-soluble, more active, less toxic analogues. Structu-
re activity relationship studies showed that substituents at ring A and at the C-7 position of 
ring B were allowed, whereas the ring E lactone was essential for activity. Two of these 
compounds are widely used in the clinic, namely topotecan (60) for the treatment of 
fluoropyrimidine-refractory ovarian and small cell lung cancers [30] and irinotecan (CPT-
11). Irinotecan (61) is a prodrug that needs to be hydrolysed by carboxylesterase [31] to its 
active metabolite SN-38 (62) (Scheme 5) It is used in colorectal cancer, showing synergism 
with cisplatin, [32] and several studies have underscored the importance of pharmacogenetic 
considerations in its clinical application [33]. 
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Scheme 5 
 
2.5.2 Topoisomerase II inhibitor 
 
 Podophyllin resin derivatives have been used as folk medicines for centuries, its main 
active ingredient being podophyllotoxin (63). In the 1950s, a search began to identify a more 
effective podophyllotoxin derivative [34] that eventually resulted in the development of a 
new class of anti-neoplastic agents which target topoisomerase II. The most important 
compounds are etoposide (64) and teniposide (65), two semi-synthetic derivatives of 4-
epipodophyllotoxin. Etoposide [35] is used mainly to treat testicular cancer which does not 
respond to other treatment and as a first-line treatment for small cell lung cancers. It is also 
used to treat chorionic carcinomas, Kaposi’s sarcoma, lymphomas, and malignant 
melanomas.  
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  63: Podophyllotoxin    64: R = CH3; Etoposide 
        65: R = 2-thienyl; Teniposide 
 
Etoposide and teniposide activity are cell cycle dependent and phase specific, with 
maximum effects on the S and G2 phases of cell division. They cause DNA damage through 
inhibition of topoisomerase II, and their mechanism of action has been studied specially for 
the case of etoposide. DNA religation inhibition by this compound seems to be due to inhibi-
tion of the release of ADP from the hydrolysis of ATP [36] and to its activation through oxi-
dation–reduction reactions to produce derivatives that bind directly to DNA. 
 
 Amsacrine (66), a large number of natural products and synthesis derivatives of 
acridines have been tested as anticancer agents and, so far, a few molecules have entered cli-
nical trials and have been approved for chemotherapy.  For instance, asulacrine (67) is an 
analog with a broader spectrum of activity in experimental tumors but without improved cli-
nical antitumor activity. DACA (XR-5000) (68) is an acridinecarboxamide and a mixed 
topoisomerase I and II inhibitor that has undergone extensive clinical trials [37]. 
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 Mitoxantrone (69) is a simplified analog of the anthracyclines. It has a complex 
mechanism of action that includes generation of a stable drug-DNA-topoisomerase II ternary 
complex. Isosteric substitution of one or more carbons of the bezene ring by nitrogen atoms 
has been employed as a strategy for the design of mixtoxantrone analogs. Pixantrone (70) has 
a high level of activity in blood related tumors and is currently being studied in Phase III 
trials for the treatment of non-Hodgkin’s lymphoma [38-39]. Another potential application of 
this drug is as an immunosuppressant in multiple sclerosis patients. The mechanism of action 
of pixantrone involves intercalation with DNA and interaction with topoisomerase II, causing 
DNA strands breaks. 
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  69: Mitoxantrone        70: Pixantrone 
 
2.6 Antibiotics with anticancer activity 
 
Anthracyclines are a group of antibiotics characterized by the presence of a planar 
chromophore containing an anthraquinone fragment, attached to an amino sugar. Doxorubicin 
(DOX) (71) and daunomycin or daunorubicin (DNR) (72) previously called adriamycin, were 
isolated from a Streptomyces species and were the first anthracycline antibiotics introduced in 
the clinic for cancer treatment. They are widely used for the treatment of human cancers, and, 
despite its very similar structure, their antitumor spectra of activity differ widely. Thus, 
daunorubicin is effective in acute lymphocytic and myeloid leukemia, while doxorubicin is 
an essential component of the chemotherapy of a large number of solid tumors, including 
breast cancer, childhood solid tumors, soft tissue sarcomas, and aggressive lymphomas. 
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71: R = CH2OH; Doxorubicin (DOX) 
72: R = CH3; Daunorubicin (daunomycin, DNR) 
 
 
Epirubicin (EPI) (73) and idarubicin (IDA) (74) [40] can be mentioned as useful al-
ternatives to DOX or DNR, respectively. EPI is an epimer of DOX at the daunosamine C-
4’position that induces pharmacokinetic and metabolic changes related to the increased 4’-O-
glucuronidation and increased elimination. In spite of this finding, clinical studies have 
shown that replacing DOX with EPI does not eliminate the risk of chronic cardiotoxicity. 
IDA, an analog of DNR obtained by removal of the methoxy group, has a broader spectrum 
of activity. This is probably related to its increased lipophilicity, which facilitates the cellular 
uptake and contributes to stabilize the ternary complex that forms the drug with DNA and 
topoisomerase II. 
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        73: Epirubicin             74: Idarubicin 
 
 
 Actinomycin D (75) (dactinomycin) is a member of the actinomycin family of 
compounds, which was isolated from several Streptomyces strains. It contains a phenoxazine 
chromophore attached to two cyclic depsipeptides containing five amino acid residues. It can 
be considered as a hybrid compound that behaves both as a DNA intercalator and a minor 
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groove binding agent. Although it differs from most intercalating drugs in that it lacks a posi-
tive charge, it has been suggested that this is compensated by its high dipole moment, arising 
from a non-symmetrical distribution of polar substituent [41]. Dactinomycin is used to treat 
sarcomas, pediatric solid tumors (e.g. Wilms’ tumor, a type of renal tumor), germ cell cancers 
(testicular cancer), and choriocarcinoma. 
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75: Actinomycin D (dactinomycin) 
 
Mitomycin C (76) is a naturally occurring antitumor quinone from Streptomyces 
caespitosus, which contains quinone and aziridine units, although not directly linked. It has 
been used as a cytotoxin since the 1960 decade and is active against a variety of tumors, 
including breast, stomach, oesophagus, and bladder, [42] as well as non-small cell lung 
cancer [43]. The N-methyl derivative of mitomycin C is also a natural product called 
porfiromycin (77), which has reached Phase III clinical studies for the treatment of head and 
neck cancer in combination with radiotherapy, with acceptable toxicity and encouraging 
activity [44]. 
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2.7 Anticancer drugs targeting tubulin and microtubules  
  
 Drugs focusing on microtubules bind to several sites of tubulin and at different positi-
ons of the microtubules. As a consequence they all suppress microtubule dynamics, thereby 
blocking mitosis at the metaphase/ anaphase transition and inducing cell death. Some of the 
well-known drugs in this mode of action are vincristine (Oncovin®), vinblastine (Velbe®), 
vindesine (Eldisin®), vinorelbine (Navelbine®), paclitaxel (Taxol®), and docetaxel (Taxtere®) 
 
 Vincristine (78) and vinblastine (79) are complex molecules produced by the leaves of 
the rosy periwinkle plant Catharanthus roseus (Vinca rosea), whose potent cytotoxicity was 
discovered in 1958. They were introduced in cancer chemotherapy in the late 1960s and 
remain in widespread clinical usage to this day. Despite their very similar structures and 
common mechanism of action, they have different toxicological properties and antitumor 
spectra. Thus, vinblastine is currently used in the treatment of Hodgkin’s disease and 
metastatic testicular tumors, where it is combined with bleomycin and cisplatin, while 
vincristine is used in the treatment of leukemia and lymphomas. Several semisynthetic 
analogs of these alkaloids [45] are also in clinical use, most notably vindesine (80), used 
mainly to treat melanoma and lung carcinomas and, associated with other drugs, to treat ute-
rine cancers, and the nor-derivative vinorelbine (81), used for non-small cell lung cancer, 
metastatic breast cancer, and overian cancer. 
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81: Vinorelbine (Navelbine®) 
 
Paclitaxel (82) is the most important natural product in cancer chemotherapy and one 
of the most successful cancer drugs ever produced, being widely used in the treatment of 
breast, ovarian, and lung carcinomas. It was isolated from the Pacific yew Taxus brevifolia, 
and its anticancer activity was discovered on the 1960s during a large-scale plant-screening 
program sponsored by the National Cancer Institute (NCI). 
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82: Paclitaxel (Taxol®) 
 
Enormous supply problems were found initially because the location of taxol in the 
bark required to sacrifice the tree to extract it, the concentration of the compound in yew bark 
is low, its extraction is complex and expensive, and the Pacific yew is a limited resource that 
grows very slowly. About 4,000 trees were required to provide 360 g of taxol for the early 
clinical trials, and 38,000 trees were necessary to isolate 25 kg of taxol to treat 12,000 cancer 
patients after approval of the use of taxol for treating advanced ovarian cancer in 1992. 
Fortunately, it was subsequently discovered that the twigs and needles of the European yew, 
Taxus baccata, were a high yielding (1 g/kg) and renewable source of a related compound, 
10-deacetylbaccatin III (83), lacking the C-13 side chain and the C-10 acetyl group, that 
could be transformed through a relatively simple semisynthetic route into paclitaxel and also 
into its more soluble and potent analog docetaxel (84), which was approved for advanced 
breast cancer in 1996 (Scheme 6). 
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Scheme 6 Semisynthetic route into paclitaxel and docetaxel. 
 
 
 
2.8 Drugs that inhibit signaling pathways for tumor cell growth and proliferation 
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 Intra- or inter-cellular communication disorders are a major cause of pathogenic 
mechanisms. For this reason, modern drug research has become increasingly focused on sig-
nal transduction therapy and many of the recently validated targets are transduction-related 
macromolecules, especially kinases. 
 
 Protein kinases (PTKs) are enzymes that regulate the biological activity of proteins by 
phosphorylation of specific amino acids with ATP as the source of phosphate, thereby 
inducing a conformational change from an inactive to an active form of the protein.  
 
 Targeting PTKs is a compelling approach to cancer chemotherapy because in many 
cancers there is an overexpression of PTKs or their associated messengers. In fact that, 
following the discovery in the early 1980s that the protooncogene Src was in fact a PTK, it 
has subsequently been proved that most PTKs are related to oncogenes. 
 
 A number of substructures related to kinase inhibitors have been in therapeutic usage 
These include compounds identified from screening studies and they include erlotinib 
(Tarceva®) (85), imatinib (Glivec®) (86), sorafenib (Nexavar®) (87), and dasatimib 
(Sprycel®) (88), natural products and their analogues such as flavopiridol (89), staurosporine 
(90), and structural analogues of ATP like roscovitine (Seliciclib®) (91) [46]. 
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 85: Erlotinib (Tarceva®)    86: Imatinib (Glivec®) 
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87: Sorafenib (Nexavar®)   88: Dasatinib (Sprycel®) 
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    89: Flavopiridol        90: Staurosporine           91:Roscovitine (Seliciclib®) 
 
Bortezomib (Velcade®) (92) was approved in 2003 for the treatment of multiple 
myeloma, the second most common hematological cancer, and is currently being clinically 
evaluated for various other malignancies. Bortezomib (PS-341, LDP-341, MLN-341) affects 
multiple signaling cascades within the cell because of proteasome inhibition and induces 
G2/M phase arrest followed by apoptosis in cancer cells [47]. 
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92: Bortezomib (Velcade®) 
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3. The aim of the studies 
 
 The aim of this research was to synthesize and modify the three core structures which 
were previously synthesized in the cancer research group to enhance their anti cancer 
activities. In continuation of these works, these studies focused on the three DNA 
intercalating core structures and a new synthetic approach to ellipticine should be examined. 
 
3.1 The first building block the study focused on was the tetracyclic carbazole derivatives 93. 
In previous works of S. Leber [48], it was shown that compound 94 is highly active against 
different cancer cell lines. Previous studies unveiled that the attachment of akylating side 
chains to this tetracyclic intercalating core resulted unexpectedly in lower activities than the 
fixation of basic side chains. As a consequence of these results and in continuation of these 
studies a number of basic or hydroxyl substituted side chains should connected to the 
carbazole nucleus and the consequences in regard to the anticancer activity should be 
evaluated. Basic substituents can enhance the activity of the intercalating structures by inter-
action with the phosphate backbone of DNA, hydroxyl groups could interact via H-bridges, 
respectively. 
N
O
O
N
R
 
 
93: R = H; 10H-Pyrido[3,4-b]carbazole-5,11-dione 94: R = CH2CH2N(CH3)2 
 
3.2 The second structure focused on in this work, was benzo[a]fluorene-5,6-dione 95. Since 
similar structures are described as highly active anticancer compounds further variations of 
ring A and D were of considerable interest [49]. 
 
 
 
 
 
95: Benzo[a]fluorene-5,6-dione 
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3.3 The third goal was to attach new side chains to the tetracyclic anthrapyrazole nucleus 96. 
The rationale for focusing on this anthrapyrazole nucleus was the fact that derivatives of 96 
exhibit anticancer activities lacking cardiotoxic side effects [50] (the major drawback of the 
anticancer drugs doxorubicin, daunorubicin, mitroxantrone etc.) Since previous syntheses of 
derivatives of 96 resulted in the formation of highly active cystatic compounds new derivati-
ves should be made accessible. 
N N
O HN
R1
R2
A B C
 
96: Anthrapyrazole  
 
3.4 Finally a new route to the antitumor alkaloid ellipticine 49 should be developed. 
 
N
N
CH3
CH3H
 
49: Ellipticine 
 
In fact of the fact that  this naturally occurring substance exhibits very interesting anticancer 
properties a new synthetic pathway should open the road to new analogs. Moreover new app-
lications of microwave irradiation to Buchwald-Hartwig coupling and ring closure reaction 
should be examined in the course of this study. 
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CHAPTER II 
 
RESULT AND DISCUSSION 
 
1. Synthesis of 10H-pyrido[3,4-b]carbazole-5,11-dione and its derivatives 
1.1 Synthesis of 10H-pyrido[3,4-b]carbazole-5,11-dione (93) 
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Scheme 7 
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Compound 93 was the starting material for the synthesis of the targeted derivatives. 
The synthesis started from the commercially available 3,4-dicarboxylpyridine 97 which was 
refluxed in freshly distilled acetic anhydride to yield the anhydride 98 in very good yield. The 
following intramolecular acylation reaction of 98 with the N-protected indole [51] under the 
catalysis of aluminium trichloride led to keto acid 101 which was subsequently esterified to 
ethyl ester 102 [52]. Reaction with lithium-bis(trimethylsilyl)amide [53] at -40 oC for 2 hours 
efforted the desired structure 93 in four steps in 13.1% over all yield as depicted in scheme 7. 
 
1.2 Synthesis of 10-((2-[tert-Butyl-diphenyl-silanyloxy]-ethylsulfanyl)-ethanol)-10H-
pyrido[3,4-b]carbazole-5,11-dione (107) 
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Scheme 8 
  
The attachment of the hydroxyl alkylsulfide side chain to compound 93 should be 
achieved by N-alkylation. First of all, the alkylchloride 105 had to be synthesized from 
compound 103. Monoprotection was realized by reaction with equimolar amounts of tert-
butyldiphenylchlorosilane to produce the protected alcohol 104 which was subsequently 
converted by treatment with thionylchloride in dichloromethane to alkyl chloride 105. In the 
following, N-alkylation of 93 with 105 could be realized by using sodium hydride in absolute 
DMF to yield 106. Following deprotection of 106 led to 107 in good yield (79.8%) as shown 
in scheme 8. IR spectrum of 107 shows the signal of hydroxyl absorption broad band at 3452 
cm-1. 1H NMR spectrum shows the signal (ppm) at 2.95 (s, 2H), 2.67 (t, 2H, J = 6.4 Hz), 3.85 
(d, 2H, J = 6.5 Hz), and 4.82 (t, 2H, J = 4.5 Hz) which are attributed to alcohol sulfide side 
chain. 
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1.3 Synthesis of 10-(2-morpholinoethyl)-10H-pyrido[3,4-b]carbazole-5,11-dione (108) 
and 10-(2-pyrolidineethyl)-10H-pyrido[3,4-b]carbazole-5,11-dione (109) 
 
Morpholine and pyrolidine ethyl groups were chosen as next chains connected to 93. 
The commercially available starting material, 4-(2-chloroethyl)morpholine hydrochloride and 
4-(2-chloroethyl)pyrrolidine, respectively, gave the desired N-alkylation product 108 and 109  
in 43.4% and 63.4% yield, respectively, as illustrated in scheme 9.  
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Scheme 9 
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IR spectrum of 108 shows a signal of strong absorption band of ether of morpholine 
ring at 1112 cm-1. 1H NMR spectrum exhibits the signal at 2.72 (d, 2H, J = 6.4 Hz) and 4.85 
(d, 2H, J = 6.8 Hz) that are attributed to two methylene protons between chromophore and 
morpholine. The signals at 2.48 (s, 7H) and 3.84 (t, 4H, J = 4.9 Hz) are assigned to the 
methylene protons of morpholine. 1H NMR spectrum of 109 shows the signal (ppm) of two 
methylene protons of the ethylene group at 2.92 (t, 2H) and 4.87 (t, 2H, J = 7.4 Hz) and the 
signal of pyrrolidine protons are at 1.77-1.84 (m, 4H) and 2.66 (d, 4H, J = 5.1 Hz).  
 
 
1.4 Synthesis of 10-[(2-ethyl)-2-oxazolidone]-10H-pyrido[3,4-b]carbazole-5,11-dione  
(114) 
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 Moreover, after preparing the morpholine and pyrrolidine derivatives 108 and 109, 
respectively, the consequences of an oxazolidine moiety to the biological activities were of 
interest. For that intention N-(2’-hydroxyethyl)-2-oxazolidone 112 had to be synthesized as 
starting material: diethanolamine 110 reacted smoothly with diethyl carbonate 111 and 
sodium methoxide to the hydroxyl ethanol derivative 112 which was treated with 
thionylchloride in dichloromethane and a small amount of absolute dimethylformamide to 
obtain N-(2’-chloroethyl)-2-oxazolidone 113 [54]. In the following compound 93 was treated 
with sodium hydride in absolute dimethylformamide in the presence of 113. Surprisingly, it 
was necessary to heat at 70 oC for 6 days to obtain desired product 114 as shown in scheme 
10.  
 
 
1H NMR spectrum of 114 shows signals (ppm) at 3.76 (t, 2H, J = 6.3 Hz) and 4.93 (t, 
2H, J = 6.3 Hz) which are assigned to the side chain whereas the signal at 3.37 (t, 2H, J = 7.5 
Hz) and 4.11 (t, 2H, J = 7.5 Hz) are attributed to two methylene protons of oxazolidine ring. 
The IR spectrum of 114 shows definitely a strong absorption band of carbonyl of oxazolidine 
ring at 1744 cm-1. Since the carbamate moiety is susceptible to enzymatic hydrolysis 
compound 114 should act as precursor thus releasing the hydroxyl ethylamine derivative as 
active compound 115 as illustrated in scheme 11. 
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Scheme 11 
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1.5 Synthesis of 3-(4-methylpiperazin-1-yl)-10-vinyl-10H-pyrido[3,4-b]carbazole-5,11-
dione (119) and Synthesis of 10-[4-(1-methylpiperazine)]-10H-pyrido[3,4-b]carbazole-
5,11-dione (120) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 12 
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Attempts to attach the 4-chloroethyl-1-methylpiperazine to compound 93 by simple 
N-alkylation to give 120 failed (Scheme 12), a route via chlorotheyl derivative 116 and sub-
sequent alkylation with N-methyl piperazine seemed promising. Indeed, compound 116 was 
easily accessible by alkylation 93 with 1-bromo-2-chloroethane in 85.1% yield. 
 
Surprisingly, reaction of 1-methylpiperazine/NaH with 116 in DMF did not furnish 
the desired product 120. NMR elucidation (Figure 5) led to the confirmation of structure 119 
as main product of this reaction. It is evident that the sodium amide generated of N-methyl 
piperazine attacked the pyridine ring which suffers from a distinct electron deficit. In the 
following the basic conditions led to HCl elimination finally leading to unexpected product 
119, as illustrated in scheme 13. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 13 The possible mechanism of the formation of 119 
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The elucidation of 119 was determined by 2D-NMR and Nuclear Overhauser 
Enhancement (NOE) as depicted in figure 5. There was an effect to detect of H-6’ and H-4 
while there was no effect between H-2’’ and H-2’ and H-6’. Moreover, H-2’’-trans and H-
2’’-cis had an effect on H-9 and H-1’’, respectively. The spectroscopy analysis obviously 
confirmed structure 119. 
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 Figure 5 Observed NOE of 119  
 
In the same way the use of KI/K2CO3 in DMF [55] produced olefin 119 in 16.0%. 
Finally the synthesis of the target compound 119 was enforced by preparing the iodo deriva-
tive 117 (Scheme 12), from 116 with NaI in acetone. The mass spectrum shows m/z 402 (M+) 
and the shift of the adjacent methylene carbon indicated the successful halide exchange.  
 
In the following the iodo compound 117 smoothly reacted with N-methyl piperazine 
to the desired product 120 by exclusive nucleophilic substitution as shown in scheme 12. 1H 
NMR spectrum of 120 shows the signal at 2.24 (s, 3H), 2.39 (s, 4H), 2.61 (s, 4H), 2.77 (t, 2H, 
J = 7.0 Hz), 4.83 (t, 2H, J = 6.9 Hz) which are attributed to the piperazine moiety. 
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1.6 Synthesis of 10-(2-((2-hydroxylethyl)(methyl)amino)ethyl)-10H-pyrido[3,4-b] 
carbazol-5,11-dione (124) 
 
The production of 124 was realized by two synthetic routes: First 2-
(methylamino)ethanol 121 was protected by tert-butyldiphenylchlorosilane to provide 
protected amine 122 in quantitative yield. The reaction of 117 and O-protected amino alcohol 
122 afforded after refluxing for 5 days compound 123 in 33.5% which was deprotected the 
use of  Bu4NF to obtain alcohol 124 in 23.4%. On the one hand, target compound 124 could 
be directly synthesized from 117 and the use of the unprotected amine 121 by simply 
nucleophilic substitution in EtOH and THF, as shown in scheme 13. 
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Both synthetic pathways showed the same results of spectroscopic data. The IR 
spectrum of 124 exhibits the signal of hydroxyl absorption broad band at 3422 cm-1. The 1H 
NMR spectrum of 124 shows signals at 2.44 (s, 3H), 2.64 (t, 2H, J = 5.3 Hz), 2.91 (t, 2H, J = 
7.0 Hz), 3.50 (t, 2H, J = 3.5 Hz), and 4.81 (t, 2H, J = 6.8 Hz) which are attributed to amino 
alcohol side chain, attached to the chromophore.  
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2. Synthesis of benzo[a]fluorene-5,6-dione derivatives 
 
 Since it was shown in previous papers that 6,7-dichloroquinoline-5,8-dione 126a 
reacted with 2-aminopyridine 142 derivatives to tetracyclic ortho-quinone systems like A and 
A’ [56] the behavior of the aza-isomer 126 in similar reactions should be studied. Moreover 
this tetracyclic nucleus seems to exhibit anticancer activity. 
 
 
 
 
 
 
 
 
 
 
 
2.1 Synthesis of 5-chloropyrido[1’,2’-1,2]imidazo[4,5-f]isoquinoline-5,6-dione (128a) and 
5-chloropyrido[1’,2’-2,3]imidazo[4,5-f]isoquinoline-5,6-dione (128b) 
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Chloroxidation of 125 by using NaClO3 in concentrated hydrochloric acid had been 
published. They obtained 126 in 3% from 125. However, this yield could be raised to 11% by 
substituting concentrated nitric acid in stead of NaClO3 [57]. 
 
 The reaction between 126 and 127 under refluxing in ethanol in the presence of 
potassium bicarbonate produced two isomers of 4-membered ring 128a and 128b [49] which 
were confirmed by 2D NMR technique. For 128a, the irradiation at δ 8.92 ppm (H-2) and δ 
7.88 ppm (H-10) had an effect on δ 8.02 ppm (H-1) and δ 8.05 ppm (H-11), respectively. 
This result indicated that the proton at δ 8.92 ppm (H-2) is adjacent to the proton at δ 8.02 
ppm and the proton at δ 7.88 ppm is close to the proton at δ 8.05 ppm. The comparison of the 
proton and carbon chemical shift of both is shown in figure 6. Mass spectra of both isomers 
show m/z 283 (M+) and a prominent peak at m/z 255 (M+-C=O). 
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Figure 6 The comparison of 1H and 13C NMR signal (ppm) of 128a and 128b. 
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There are two possible ways to form two intermediates 129a and 129b [56, 58-59]. 
Not only nucleophilic attacks on C-6 of 126, but also attacks on C-7 provide the resulting 
intermediates as shown in scheme 15. The predicted mechanism of the formation of 128a is 
illustrated in scheme 16. 
 
 
N
O
O
Cl
Cl
126
N
O-
N
O
N
N
R
R
H2N
O-
Cl
Cl
O
H2N
Cl
Cl
+
+
N NH2
R
129a
129b
6
7
 
Scheme 15 The formation of the initial substitution products. 
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Scheme 16 The purposed reaction mechanism of the formation of 128a. 
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2.2 Synthesis of 5-bromopyrido[1’,2’-1,2]imidazo[4,5-f]isoquinoline-5,6-dione (134a) 
and 5-bromopyrido[1’,2’-2,3]imidazo[4,5-f]isoquinoline-5,6-dione (134b) 
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 Refluxing in ethanol, compound 126 reacted with 2-amino-5-bromopyridine 133 in 
the presence of potassium bicarbonate to provide again two isomers of tetracyclic fused ring 
134a and 134b which show the close Rf values (Rate of flow) in 4:4:1 ethylacetate: light pet-
roleum:methanol. The Rf value of 134a is 0.36 and 134b is 0.45. Thus, 134b could not be 
definitely separated from 134a due to the close Rf values of both compounds. It is less soluble 
than 134a in DMSO-d6. 1H and 13C NMR in DMSO-d6 of it mainly consist of 134a but it 
shows the different proton chemical shift on ring A. Moreover, two carbonyl groups of 134b 
show a little different carbon chemical shift from 134b. Therefore, there could not be 
elucidated whole protons and carbons of 134b because of contamination with 134a. The 
comparison of 1H and 13C NMR of both is shown in figure 7. However, both mass spectra 
show a prominent peak at m/z 312 (M+). 
 
 
 
 
 
 
 
 
  
 
 
52
 
 
 
 
N
O
O
N
N
Br
134a
H
H
H
H
HH
A B
C
D
9.06 (s)
8.92 (s)
8.03 (s)
9.29 (s)
7.89 (s)
8.00 (s)
149.4
155.6
117.5
137.6
125.1
180.3
167.3
121.8
148.4
147.6
119.3
133.4
111.4
127.8
 
 
 
N
O
O
N
N
Br
134b
H
HH
H
H
H
7.83 (d, J=5.0Hz)
8.88 (d, J=5.0 Hz)
A B
C
D9.30 (s)
180.1
167.2
120.8
152.8
145.3 128.8
 
 
Figure 7 The comparison of 1H and 13C NMR signal (ppm) of 134a and 134b. 
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2.3 Synthesis of 5-nitropyrido[1’,2’-1,2]imidazo[4,5-f]isoquinoline-5,6-dione (136) 
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In case of strong electron withdrawing groups such as nitro group on pyridine ring, 
the tetracyclic fused ring 136a or its isomer 136b could not be observed when 126 was 
treated with 135 under basic conditions. Otherwise, acid conditions were considered to 
prepare 136a. Ceriumtrichloride heptahydrate was used instead of potassium bicarbonate in 
this reaction and furnished 136a. Its structure was clearly elucidated by 2D NMR technique. 
The assignment of protons and carbons are illustrated in figure 8. The mass spectrum of 136a 
shows m/z 249 (M+) and a prominent peak at m/z 221 (M+-C=O). 
 
 
 
 
 
 
 
 
 
 
Figure 8 Assignment of 1H and 13C NMR of 136. 
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Moreover, it was not possible to obtain the product from the reaction between quinone 
126 and substituted aminopyridines which have more than two electron withdrawing groups. 
The reaction could not realized, neither in the presence of potassium bicarbonate nor cerium 
trichloride heptahydrate, as illustrated in scheme 17. 
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Scheme 17 
 
 
2.4 Synthesis of 5-chloropyrido[1’,2’-1,2]imidazo[4,5-f]-2-((2-(dimethylamino)ethyl) 
methylamino) isoquinoline-5,6-dione (138b) 
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 Since the tetracyclic nucleus of 128a is flat and therefore can act as DNA-intercalator 
a basic side chain should be attached to improve eventually the anticancer activity. Therefore, 
nucleophilic substitution of 128a with secondary amine 137 should give 138a. 
 
 But nucleophilic aromatic substitution of 128a with secondary amine 137 [60-61] 
afforded undesired product 138b. The structure of 138b was determined by 2D-NMR 
technique. The irradiation of proton at δ 7.60 ppm, attributed to H-10, had an effect on δ 7.75 
ppm (H-11) and showed the same coupling constant AB system (J = 9.5 Hz). Moreover, the 
irradiated proton at δ 7.18 ppm (H-1) culminated in the proton of the methyl group at δ 3.31 
ppm (-NCH3) while irradiation of proton methyl group influenced the proton at δ 7.18 ppm 
(H-1). That result confirmed that amine 137 obviously attacked on C-2. HRMS shows 385.12 
m/z (M++1) as a prominent peak. 
 
 
2.5 Synthesis of pyrido[1’,2’-1,2]imido[4,5-f]quinazoline-5,6-dione (143a) 
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46.2 %
139 140
141
142
143a
N
N
N
N
O
O
143b
+
not observed
 
Scheme 18 
 
 
 
 
  
 
 
56
 The reductive cyclization of 139 with Zn metal in glacial acetic acid provided 
pyrimidine 140 which was oxidized to 141 by concentrated hydrochloric acid and nitric acid 
[57]. In refluxing EtOH compound 141 was treated with 2-aminopyridine 142 in the presence 
of potassium bicarbonate. The reaction proceeded straightforward furnishing solely 143a. 
Isomer 143b could not be detected. There were expected two tentative isomers 143a and 
143b from the reaction between 141 and 142 under basic conditions as shown in scheme 18. 
The best confirmation is 2D NMR technique, HMQC, which showed that H-4 has an effect 
on C-5 as shown in figure 9. 
 
 
 
  
 
 
 
Figure 9 Observed NOE of 143a 
 
 
 Finally the hitherto unstudied reaction of pyrimidine quinone 141 with 2-
aminopyridine 142 should be examined. 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
N
N
N
O
O
1 1 3 a
H
4
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3. Synthesis of anthrapyrazole derivatives  
 
3.1 Synthesis of 2-(2-(dimethylamino)ethyl)-5-chloroindazolo[4,3-gh]isoquinoline-6(2H)-
one (153) 
N N
O HN
R1
R2
A B C
 
96: anthrapyrazole  
 
The syntheses of derivatives of 96 starts from the tetracyclic nucleus 153 as depicted 
in scheme 19. It has been proven that the tetracyclic nucleus interacts with the DNA by 
intercalation [62]. In continuation of previous studies the effect of new side chains attached to 
the tetracyclic core should be examined. 
 
N
Cl
N
Cl
CO2H
N
Cl
CO2CH3
LDA / CO2
81.0 %
diazomethane
Et2O 95.0 %
144 145
146
 
 
Cl
CH3
F
Cl
F
BrNBS/benzoylperoxide
57.9 %
147 148
Zn/THF
Cl
F
ZnBr
148a
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Cl
F
Br
N
Cl
CO2CH3
N
CO2CH3
F
Cl
N
CO2H
F
Cl
N
F
ClO
O
N
ClO
N
H
NH2N
N N
N
1. Zn/THF
2. Ni(PPh3)2Cl
73.6 %
NaOH/ H2O
87.3 %
fuming H2SO4
59.0 %
NEt3  79.0 %
149
150
151
152
153
148
146
 
Scheme 19 
 
 Commercially available 3-chloropyridine 144 on treatment with lithium 
diisopropylamide and carbon dioxide gas led to acid 145 which was converted to ester 146 by 
diazomethane. The key step was the nickel mediated coupling of ester 146 with 148a. This 
organo zinc bromide reagent was easily prepared by treatment of 148 with zinc dust in 
tetrahydrofurane. Benzyl bromide 148 was prepared by treatment of 147 with N-
bromosuccinimide in carbon tetrachloride. The addition of a tetrahydrofuran solution of 148a 
to ester to 146 in the presence of bis[triphenylphosphine]nickel(II) chloride led to coupled 
product 149. Basic hydrolysis of 149 gave acid 150. Cyclization and oxidation of 150 with 
fuming sulfuric acid with concomitant demethylation, led to 151. The incorporation of 
pyrazol ring was successfully accomplished by treatment of 151 with hydrazine 152 to give 
satisfactory yields of 153 [63] after purification. 
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3.2 Synthesis of 2-(2-(dimethylamino)ethyl)-5-((3-methylthio)propylamino)indazolo[4,3-
gh]isoquinoline-6(2H)-one (155) 
 
Nucleophilic aromatic substitution (SNAr) of the 5-chloro substituted compound 153 
by 3-(methylthio)propylamine 154 in absolute pyridine for 30 hours at 115 oC provided pro-
duct 155 in 58.1 %. 
 
N
N N
O Cl
S NH2
pyr. 115 oC 30 hr
N
N N
O NH S
NN
153
154
155
 
 
 The 1H NMR spectrum of compound 155 shows the signal as a singlet at 2.13 (s, 3H) 
which is attributed to the methyl group, adjacent to sulfur atom. The signals at 2.07 (t, 2H, J = 
6.8 Hz), 2.91 (t, 3H, J = 6.7 Hz), and 3.60 (m, 2H) are the protons of three methylene groups 
of amino sulfide side chain that connected to compound 153. The amine proton, adjacent to 
the aromatic ring, shows a triplet at 9.20 (br., 1H, J = 5.4 Hz). 13C NMR of the side chain 
shows signals at 15.5, 28.5, 31.4, and 41.6 ppm. IR of 155 shows the signal of the –NH stret-
ching band at 3273 cm-1. The 1H and 13C NMR in CDCl3 of the chromophore compound 155 
is shown in figure 10.  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
60
 
 
 
 
N
N N
N
O HN S
H
H
H
H
H9.26 (S)
8.77 (d,J=5.3 Hz)
8.25 (d,J=5.2 Hz)
7.66 (d,J=9.2 Hz)
6.98 (d,J=9.2 Hz)
4.60 (t,J=6.8 Hz)
2.68 (t,J=6.9 Hz)
2.31 (s)
1 2
56
8
10 2a
6a
10b
 
 
45.7
59.2
48.8
137.9
125.2
120.4
120.2
130.8
147.6
145.6
113.3
150.2
134.0 122.8
180.8
104.9
N
N N
N
O HN S
 
  
Figure 10 Assignment of 1H and 13C NMR of 155. 
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3.3 Synthesis of 5-(2-(1H-indol-3-yl)ethylamino)-2-(2-
(dimethylamino)ethyl)indazolo[4,3-gh]isoquinoline-6(2H)-one (157) 
 
 
N
H
NH2
pyr. 115 oC 30 hr
N
N N
O HN
N
N
N N
O Cl
N
N
H
153
156
157
 
 
 Displacement  of the 5-chloro substituted compound 153 by tryptamine 156 in absolu-
te pyridine for 30 hours at 115 oC led to product 157 in 61.5 % yield. The 1H NMR spectrum 
of compound 157 shows the protons signal at 3.23 (t, 2H, J = 6.7 Hz), 3.73 (m, 2H), 7.10-
7.20 (m, 3H), 7.38 (m, 2H), and 9.20 (t, 1H, J = 5.2 Hz) ppm which are attributed to 
tryptamine side chain. 13C NMR spectrum of compound 157 shows signals at 24.4, 45.1, 
110.8 111.4, 120.0, 121.0, 122.0, 123.3, 127.0, and 136.3 ppm which are attributed to carbon 
frame of the tryptamine. IR of 157 shows the signal of –NH stretching band at 3258 cm-1.  
 
 
3.4 Synthesis of 5-(2-(1H-imidazol-4-yl)ethylamino)-2-(2-(dimethylamino)ethyl) 
indazolo[4,3-gh]isoquinoline-6(2H)-one (159) 
 
 
pyr. 115 oC 30 hr
N
N
H
NH2
N
N N
O HN
N
N
N N
O Cl
N
153
158
159
NH
N
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 Displacement of the 5-chloro substituted compound 153 by histamine 158 in absolute 
pyridine for 30 hours at 115 oC provided product 159 in 58.3 % yield. The 1H NMR spectrum 
of compound 159 shows proton signals at 3.03 (d, 2H, J = 6.2 Hz), 3.65 (d, 2H, J = 5.8 Hz), 
6.96 (s, 1H), and 7.61 (s, 1H) ppm which are attributed to histamine side chain. 13C NMR 
spectrum of compound 159 shows the signal at 29.6, 43.0, 116.2, 135.2, and 135.5ppm which 
are attributed to carbon frame of histamine. IR of 159 shows the signal of –NH stretching 
band at 3422 cm-1.  
 
3.5 Synthesis of 2-(2-dimethylamino)ethyl)-5-(2-(pyridin-2yl) ethylamino)indazolo[4,3-
gh]isoquinoline-6(2H)-one (161) 
 
 
N NH2
pyr. 115 oC 30 hr
N
N N
O
N
N
N N
O Cl
N
HN N
153
160
161
 
Displacement  of the 5-chloro substituted compound 153 by 2-(2-aminoethyl)pyridine 
160 in absolute pyridine for 30 hours at 115 oC gave product 161 in 47.4 %. The 1H NMR 
spectrum of compound 161 shows the protons signal at 3.23 (t, 2H, J = 6.7 Hz), 3.73 (m, 2H), 
7.13-7.22 (m, 3H), 8.6 (d, 1H, J= 4.7 Hz), and 9.31 (t, 1H, J = 5.3 Hz) which are attributed to 
pyridine side chain. 13C NMR spectrum of compound 161 shows signals at 38.0, 42.8, 121.8, 
123.6, 149.6, and 158.2 ppm which are attributed to the pyridine side chain. IR of 161 shows 
the signal of –NH stretching band at 3289 cm-1.  
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3.6 Synthesis of 2-(2-(dimethylamino)ethyl)-5-(2-(1-methylpyrrolidin-2-yl)ethylamino) 
indazolo[4,3-gh]isoquinoline-6(2H)-one (163) 
 
 
N
N N
O HN
N
N
NH2
pyr. 115 oC 30 hr
N
N N
O Cl
N
N
153
162
163
 
 
 
 Displacement of the 5-chloro substituted compound 153 by 2-(2-aminoethyl)-1-
methylpyrrolidine 162 in absolute pyridine for 30 hours at 115 oC led to product 163 in good 
yield (85.8 %). The 1H NMR spectrum of compound 163 shows proton signals at 1.72-1.86 
(m, 6H), 3.52 (m, 4H), and 9.23 (br., s, 1H) which are attributed to pyrrolidine side chain. 13C 
NMR spectrum of compound 163 shows the signal at 33.1, 40.5, 40.6, 32.0, 30.6, 57.1, and 
63.9  ppm which are attributed to carbon frame of the pyrrolidine side arm. IR of 163 shows 
the signal of –NH stretching band at 3282 cm-1. 
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3.7 Synthesis of 2-(2-(dimethylamino)ethyl)-5-(2-(thiophen-2-yl) 
ethylamino)indazolo[4,3-gh]isoquinoline-6(2H)-one (165) 
 
 
 
S
NH2
pyr. 115 oC 30 hr
N
N N
O
N
N
N N
O Cl
N
HN S
153
164
165
 
 
 
 
Displacement of the 5-chloro substituted of compound 153 by 2-thiopheneethylamine 
164 in absolute pyridine for 30 hours at 115 oC gave product 165 in 58.3 % yield. The 1H 
NMR spectrum of compound 165 shows proton signals at 3.29 (t, 2H, J = 7.0 Hz), 3.75 (m, 
2H), 7.10-7.20 (m, 3H), 7.38 (m, 2H), 6.37 (m, 3H) , 7.18 (m, 1H), and 9.27 (t, 1H, J = 5.6 
Hz) ppm. The integration of proton signals at 6.37 are three protons. One of them belongs to 
H-4. 13C NMR spectrum shows the signals at 30.0, 48.8, 125.2, 125.7, and 127.1 ppm which 
are attributed to the thiophene side chain. IR of 165 shows the signal of –NH stretching band 
at 3286 cm-1. 
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4.Synthesis of ellipticine (49) 
 
 Finally a new and very short route to ellipticine 49 should be opened: starting from 
bromoisoquinoline derivative 169 a two step approach should be tried. A Buchwald-Hartwig 
reaction followed by an intermolecular reaction should be lead on the shortest route to 
ellipticine. 
 
4.1 Synthesis of 7-bromo-5,8-dimethylisoquinoline (169) 
166
Br
Br
Br
O
1. n-BuLi / THF/ -78 oC
2. DMF rt  1 hr.
             95.8 %
O O
160 oC, 90 min
84.4%
Br
N
NH2
O
O
Br
N
H2SO4/ P2O5
160 oC, 45 min
17.2%
167
168 169
 
Scheme 20 
 
Treatment of 1,4-dibromo-2,5-dimethylbenzene 166 with n-BuLi followed by the ad-
dition of DMF produced the aldehyde 167 [64] which could be converted to imine 168 by 
refluxing in aminoacetaldehyde diethyl acetal to yield the expected product [64]. The 1H 
NMR spectrum of 168 shows a singlet 8.48 which is attributed to the proton of imine. The 
signal of 1.19 (t, 6H, J = 7.0 Hz), 3.55 (dd, 2H, J = 2.2, 7.0 Hz), 3.68 (dd, 2H, J = 2.3, 7.0 
Hz), 3.76 (d, 2H, J = 2.0 Hz), and 4.79 (t, 1H, J = 2.0 Hz) which are the proton of acetal 
moiety. Imine 168 allowed to cyclize in hot H2SO4/P2O5 to provide isoquinoline 169. The 1H 
NMR signals of 169 exhibit 7.74 (s, 1H), 7.75 (d, 1H, J = 5.9 Hz), 8.60 (d, 1H, J = 5.9 Hz), 
and 9.37 (s, 1H) which are the protons of aromatic isoquinoline ring (Scheme 20). The syn-
thesis of intermediate 169 has been reported recently [65] in 8 steps, while it can be done now 
in 3 steps with this strategy. 
 
  
 
 
66
4.2 Attempts to synthesis of ellipticine (49) 
 
 
 
 
 
 
 
 
       
 
 
 
 
 
 
 
 
       Ellipticine  
 
 
 
 
 
 
 
 
     Not Observed 
 
Scheme 21 
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The Pd-catalyzed amination of 169 with 2-chloroaniline in the presence of Pd(OAc)2, 
PtBu3, and NaOtBu led to product 170 (14.3%) and 171 (9.6%) [66]. Unfortunately, 
ellipticine 49 could not be done in a tandem reaction by Buchwald-Hartwig coupling and ring 
closure in one pot. Moreover, subsequent intramolecular Heck reaction of compound 170 
gave only 171. Besides that compound 171 could be directly achieved from 169 and aniline 
by Buchwald-Hartwig reaction in 42.0%.  
 
 The attempts to cyclize 171 to ellipticine (49) by intramolecular Heck reaction using 
Pd(OAc)2, could not realized, neither under conventional conditions nor under microwave 
assistance. The possible reason of this step it might be steric hindrance from methyl group 
that blocks the insertion step (Scheme 22). This seems reasonable because similar cyclization 
with adducts lacking this unfavorable methyl group occur smoothly [67]. 
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H CH3
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Scheme 22 Mechanism of intremoleculaer Heck reaction to form elliptine. 
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5. Biological activities test of synthesized compounds 
 
 All synthesized compounds were tested the biological activites in vitro at Zentaris 
GmbH. The antiproliferative activities were evaluated on two different cell lines; NClH460: 
lung carcinoma, SKOV3: ovrian carcinoma. The primary screen was carried out at constant 
concentration of 3.16 µg/ml.  
 
 For the first series, carbazole nucleus (Scheme 23) compound 107-109, 114, 120, and 
124 showed strongly antiproliferative activity against NClH460 cell lines. In case of SKOV3 
cell lines, compound 109, 114, and 120 exhibited moderately antiproliferative activity 
whereas compound 107, 108, and 124 showed higher than the concentration constant at 3.16 
µg/ml especially 107 and 124 as shown in table 1. 
 
N
O
O
N
R
 
 
 107: R = -(CH2)2S(CH2)2OH            108: R = -(CH2)2-N-morphorine 
109: R = -(CH2)2-N-pyrrolidine            114: R = -(CH2)2-N-oxazolidine 
120: R = -(CH2)2-N-1-methylpiperazine     124: R = -(CH2)2NMe(CH2)2OH 
 
Scheme 23 
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Table 1 Cytotoxicity of the series of carbazole nucleus 
 
Cell lines 
Compounds 
 
NClH460 EC50 (µg/ml) 
 
SKOV3 EC50 (µg/ml) 
107 0.6388 9999 
108 0.7924 3.9310 
109 0.2562 0.5944 
114 0.3099 2.3770 
120 0.5275 1.3390 
124 0.8301 9999 
 
 
The biological activity test of the series of benzo[a]fluorine-5,6-dione (95) and 
anthrapyrazole (96) are under progress. 
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CHAPTER III 
 
CONCLUSION 
 
The derivatives of three structures, 10H-pyrido[3,4-b]carbazol-5,11-dione (93), 
benzo[a]fluorine-5,6-dione (95), and anthrapyrazole (96), were designed and synthesized. 
First series, carbazole derivatives were modified by N-alkylation with various side chains, 
leading to product 107-109, 114, 120, and 124 which showed strong anticancer activity 
against NClH460 cell lines whereas especially 109, 114, and 120 presented moderate 
cytotoxicity against SKOV3 cell lines. Nevertheless the high anticancer activities of the 
previously synthesized amines could not be exceeded. The second series was the reaction 
between 6,7-dichloro-5,8-isoquinoline dinone/6,7-dichloro-5,8-quinazoline and substituted 2-
aminopyridine/2-aminopyridine led to 128(a-b), 134(a-b), 136a and 143a. Surprisingly, 128a 
could be substituted by secondary amine at C-2 to provide 138b. The third series 
anthrapyrazole was synthesized by nucleophilic aromatic substitution (SNAr) of the 5-chloro 
substituted 153, leading to 155, 157, 159, 161, 163, and 165. For the second and the third 
series the testing of anticancer activity are in progress and therefore conclusion about structu-
re activity relationships can not be drawn at this time. Finally, a new and extreme short route 
to ellipticine (49) could not be realized by a tandem Buchwald-Hartwig coupling and Heck 
reaction. However, the key intermediate 169 which can be converted to ellipticine, could be 
done in 3 steps. 
 
 
 
   
 
107: R = -(CH2)2S(CH2)2OH  108: R = -(CH2)2-N-morphorine        
109: R = -(CH2)2-N-pyrrolidine  114: R = -(CH2)2-N-oxazolidine 
120: R = -(CH2)2-N-1-methylpiperazine 124: R = -(CH2)2NMe(CH2)2OH       
                              
 
 
 
 
 
 
 
 
 
128a:  X = N, Y = C, Z = C ; R1 = Cl, R2 = H       128b:  X = C, Y = N, Z = C ; R1 = Cl, R2 = H    
134a:  X = N, Y = C, Z = C ; R1 = Br, R2 = H       134b:  X = C, Y = N, Z = C ; R1 = Br, R2 = H 
136a:    X = N, Y = C, Z = C ; R1 = NO2, R2 = H  138b:    X = N, Y = C, Z = C ; R1 = Cl, R2 = -NMe(CH2)2NMe2                     
143a:  X = N, Y = C, Z = N ; R1 = H, R2 = H               
NH
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H
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1 5 5 :  R  =  - ( C H 2 ) 3 S C H 3
1 5 7 :  R  =  
1 5 9 :  R  =
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N
O
O
N
R
N N
O HN
N
R
X
Y
Z
N
N
O
O
R1
R2
Br
N
169
  
 
 
71
CHAPTER IV 
 
Experimental Part 
 
1.Synthesis of 10-H-pyrido[3,4-b]carbazole-5,11-dione and its derivatives. 
 
1.1 Synthesis of furo[3,4-c]pyridine-1,3-dione (98) 
 
N
O
OH
O
OH
Ac2O
reflux
89.7%
N
O
O
O
97 98
 
 
 A solution of 3,4-dicarboxylpyridine 97 (15.00 g, 0.09 mol) in 54 mL distilled acetic 
anhydride was refluxed for 30 min. After cooling down to room temperature, the excess of 
solvent was removed by vacuum distillation (20 mbar at 70 -100 oC) until total dryness. The 
dark brown semi-solid was kept in KOH a desiccator over night. The solid was purified by 
sublimation to yield 98 (12.00 g, 89.7 %) as solorless crystals. The full characterization of 
compound 98 is in reference [52]. 
 
1.2 Synthesis of 1-phenylsulfonyl-1H-indole (100) 
 
N
H
NaH/THF
PhSO2Cl
75.0%
N
SO2Ph
99 100
 
 
 During 20 min, NaH (2.60 g, 0.108 mol, 60% in paraffin) was added to a stirred solu-
tion of indole 99 (10.00 g, 0.085 mol) in 100 mL anhydrous THF at 0 oC. After stirring at RT 
for 1 h, benzenesulfonylchloride (11mL, 0.086 mol) was added slowly. The reaction mixture 
was stirred for an additional 1 hr and then poured into 900 mL of 5% NaHCO3 and extracted 
with ether (5 x 300 mL). The combined organic layers were dried with Na2SO4 and the sol-
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vent was removed under reduced pressure to give a beige solid. Recrystallization with ethanol 
gave the compound 100 (16.57 g, 75.0%) as colorless crystals, mp 75-78 oC. The full 
characterization of compound 100 is in reference [51]. 
 
 
 
1.2 Synthesis of 1-(phenylsufonyl)indol-3yl-3-carboxy-4-pyridyl ketone (101) 
 
 
N
O
O
O
1. AlCl3/CH2Cl2
2.
N
SO2Ph
N
PhO2S
O
N
HOOC
98.7%
98
100 101
 
   
 To a magnetically stirred suspension of AlCl3 (12.51 g, 0.093 mol) in CH2Cl2 (250 
mL) was added pyridine-3,4-dicarboxylic acid anhydride 98 (7.19 g, 0.048 mol), and the 
mixture was stirred for 30 min at RT. A solution of 1-phenylsulfonyl-1H-indole 100 (3.40 g, 
0.013 mol) in CH2Cl2 (50 mL) was added dropwise via an additional funnel, and the solution 
was stirred for 2 hr at RT. The mixture was quenched with ice-water (250 mL), and the 
resulting solid was collected and dried in a desiccator over night. The solid was dissolved in 
acetone (350 mL) and refluxed for 1 h. Concentration of the solution to half volume gave 
white crystals which were collected in three crops, affording 101 (3.52 g, 99.7 %) as pale 
yellow crystal. The full characterization of compound 101 is in reference [52]. 
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1.4 Synthesis of 1-(phenylsufonyl)indol-3-yl-3-carbethoxy-4-pyridyl ketone (102) 
 
 
N
PhO2S
O
N
HOOC
pTsOH.H2O/Toluene/EtOH
reflux   5 days
81.7%
N
PhO2S
O
N
EtOOC
101
102
 
 
 
 A mixture of keto acid 101 (4.84g, 11.9 mmol), absolute EtOH (200 mL), toluene 
(500 mL) and p-toluenesulfonic acid monohydrate (3.60 g, 18.9 mmol)  was refluxed for 5 
days under azeotropic removal of water. The solvent was removed in vacuo, ethyl acetate 
(400 mL) was added, and then the mixture was washed with 10% aqueous NaHCO3 (3 x 250 
mL). The organic layer was washed 2 times with water (200 mL) and dried with Na2SO4. 
After filtration, the solvent was removed to yield a beige solid. The crude product was 
purified by column chromatography using 1:1 THF/EtOAc as eluent to give 4.22 g (81.7%) 
102 as colorless crystals. The full characterization of compound 102 is in reference [52]. 
 
 
1.5 Synthesis of 10H-pyrido[3,4-b]carbazole-5,11-dione (93) 
 
N
H
N
O
O
LiN[Si(CH3)3]2
THF   -40 OC
29.9%
93
N
PhO2S
O
N
EtOOC
102
 
 
 To a solution of keto ester 102 (2.20 g, 46 mmol) in anhydrous THF (100 mL) at -76 
oC was slowly added 1.0M Li-bis(trimethylsilyl)amide (10.40 mL, 10.4 mmol). The mixture 
was allowed to warm up to -40 oC for 2 h under argon atmosphere. Then the mixture was 
warmed up to RT and the solvent was removed in vacuo to give a dark oil. The resulting oil 
was quenched with saturated NH4Cl solution (200 mL) and extracted with EtOAc (5 x 150 
mL). The combined organic phases were dried with Na2SO4 and the solvent was evaporated. 
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The crude product was purified by column chromatography, using 40% light petrole-
um/EtOAc as eluent to obtain product 93 as orange crystals, mp 318-320 oC (0.358 g, 
29.88%). The fully characterization of compound 93 is in reference [52]. 
 
 
1.6 Synthesis of 2-[2-(tert-butyl-diphenyl-silanyloxy)-ethylsulfanyl]-ethanol (104) 
 
HO
S
OH
imidazole/CH2Cl2
Si
Cl
Ph
Ph S
O
Si
Ph
Ph
HO
65.0%
103 104
 
 
 A solution of tert-butyldiphenylchlorosilane 103 (7.52 mL, 29.4 mmol) in  CH2Cl2 (10 
mL) was added dropwise to a solution of bis-(2-hydroxyethyl)-sulfide (2.94 mL, 29.4 mmol) 
in CH2Cl2 (34 mL) and stirred at 0 oC for 1 h. Then the mixture was allowed to warm up to 
RT and was continuously stirred for 2 h. After that water was added and the mixture was 
extracted by EtOAc. The combined organic layers were washed with water and dried with 
Na2SO4 and the solvent was evaporated. The crude product was purified by column 
chromatography, using 30% EtOAc/light petroleum as eluent to provide 104 (6.89 g, 65.0%) 
as colorless liquid. 
 
1H NMR (200 MHz, CDCl3): δ  = 1.07 (s, 9H, -C(CH3)3), 2.33 (s, 1H, -OH), 2.64-2.67 
 (m,4H, -CH2SCH2-), 3.63 (s, brs, HOCH2CH2S-), 3.81 (t, 2H, J = 6.8 Hz,-SCH2CH2
 
OSi-), 7.39-7.45 (m, 4H, Ph), 7.66-7.71 (m, 6H, Ph). 
13C NMR (50MHz, CDCl3): δ = 19.1 (C(CH3)3), 26.7 (C(CH3)3), 33.6 (HOCH2CH2S-),35.5 
 (-SCH2CH2OSi-), 60.4 (HOCH2CH2S-), 63.7 (-SCH2CH2OSi-), 127.7 (Ph), 129.7, 
 (Ph),133.3 (Ph), 135.5 (Ph). 
MS m/e (% relative intensity): 225(100), 199(24.1), 181(59.2), 105(8.9), 77(12.2) 61(7.1), 
 45(8.5). 
IR (NaCl disc) υmax: 3405, 2956, 2930, 2857, 1472, 1427, 1112, 823 cm-1. 
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1.7 Synthesis of tert-butyl-[2-(2-chloro-ethylsulfanyl)-ethoxy]-diphenylsilane 
 (105) 
 
SOCl2/CH2Cl2
S
O
Si
Ph
Ph
Cl
94.5 %
S
O
Si
Ph
Ph
HO
104 105
 
 
The alcohol 104 (2.24 g, 6.2 mmol) was dissolved in absolute CH2Cl2 (7 mL) then 
SOCl2 (1.80 mL, 24.9 mmol) was added dropwise to the resulting solution. Afterwards, the 
mixture was stirred for 40 min at RT.  Saturated NaHCO3 (200 mL) was added and stirred for 
10 min. The water layer was extracted with CH2Cl2 (100 mL x 2). The combined organic 
phases were washed with saturated NaHCO3 (190 mL) and dried with Na2SO4. The solvent 
was evaporated to give 2.234g (94.5%) of 105 as beige liquid. 
 
 
1H NMR (200 MHz, CDCl3): δ = 1.06 (s, 9H, -C(CH3)3), 2.67 (t, 2H, J = 6.8 Hz -SCH2CH2
 
OSi-), 2.79 (t, 2H, J = 8.3 Hz, ClCH2CH2S-), 3.52 (t, 2H, J = 7.7 Hz, ClCH2CH2S-), 
 3.80 (t, 2H, J = 6.8 Hz, -SCH2CH2OSi-), 7.39-7.45 (m, 4H, Ph), 7.65-7.67 (m, 6H, 
 Ph). 
13C NMR (50MHz, CDCl3): δ = 19.1 (C(CH3)3), 26.8 (C(CH3)3), 34.2 (ClCH2CH2S-),34.4 
 (-SCH2CH2OSi-), 43.0 (ClCH2CH2S-), 63.9 (-SCH2CH2OSi-), 127.7 (Ph), 129.8 (Ph),
 133.3 (Ph), 135.5 (Ph). 
MS m/e (% relative intensity): 323(12.1), 321(27.4), 217(57.7), 181(24.7), 157(14.8), 
 105(100), 77(15.3), 45(17.6). 
IR (NaCl disc) υmax: 3070, 2958, 2930, 2857, 1472, 1427, 1112, 823 cm-1. 
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1.8 Synthesis of 10-((2-[tert-butyl-diphenyl-silanyloxy]-ethylsulfanyl)-ethanol)-10H-
pyrido[3,4-b]carbazole-5,11-dione (106) 
 
 
105
O
N
N
H
O
S
O
Si
Ph
Ph
Cl
NaH/ DMF
O
N
N
O
S
O
Si
Ph
Ph
43.4 %
10693
 
 A solution of amine 93 (0.13 g, 0.54 mmol) in absolute DMF ( 5 mL) was added 
dropwise to a cooled (-5 to -10 oC) suspension of NaH (54 mg, 1.35 mmol, 60% in paraffin, 
washed twice with hexane) in DMF  (3 mL), after 30 min of stirring sulfide 105 (0.45 g, 1.09 
mmol) in  DMF (5 mL) was added slowly and the reaction mixture was stirred at 67 oC for 6 
days.  After quenching with 50 mL of water the mixture was extracted several times with 
EtOAc and the combined organic phases were dried with Na2SO4. The solvent was removed 
under reduced pressure to give a crude product which was purified by column 
chromatography, using 40% EtOAc/ petroleumether as eluent to obtain 106 (65 mg, 43.4%) 
as orange crystals, mp 94-95 oC. 
 
1H NMR (200 MHz, CDCl3): δ = 1.02 (s, 9H, -C(CH3)3), 2.79 (t, 2H, J = 6.4 Hz, -SCH2CH2O
 Si-), 2.97 (t, 2H, J = 7.4 Hz, -NCH2CH2S-), 3.85 (t, 2H, J = 6.5Hz, -SCH2CH2OSi-), 
 4.88 (t, 2H, 7.2 Hz, -NCH2CH2S-), 7.36-7.46 (m, 8H), 7.49 (s, 3H), 7.63-7.68 (m, 
 5H), 8.43 (d, 1H, J = 6.9 Hz). 
13C NMR (50MHz, CDCl3): δ = 19.1 (C(CH3)3), 26.7 (C(CH3)3), 32.0 (-NCH2CH2S-),34.6
 (-SCH2CH2OSi-), 45.2 (-NCH2CH2S-), 63.8 (-SCH2CH2OSi-), 111.1 (C-9), 118.5 (C-
 4), 119.1 (C-5a), 123.6 (C-5b), 123.8 (C-6), 125.1 (C-11a),127.6 (Ph), 127.9 (C-8), 
 129.6  (Ph), 133.3 (Ph), 134.0 (C-10a), 135.5 (Ph), 139.2 (C-4a, C-9a), 148.2 (C-1), 
 155.5 (C-3), 178.0 (C-11), 179.5 (C-5). 
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HRMS (M++1) calculated C35H25O3N2SSi 591.2138, found 591.2146. 
IR (KBr disc) υmax: 2958, 2930, 2857, 1661, 1586, 1513, 1471, 1263, 1110, 701 cm-1. 
 
1.9 Synthesis of 10-(2-(2-hydroxyethylthio)ethyl)-10H-pyrido[3,4-b]carbazole-5,11-dione 
(107) 
 
O
N
N
O
S
O
Si
Ph
Ph
Bu4NF/THF
79.8 %
O
N
N
O
S
OH
106 107
 
 
 A solution of 1M Bu4NF (1.2 mL, 1.2 mmol) in THF was added to a solution of 
compound 106 (0.28 g, 0.48 mmol) in absolute THF (10 mL) and the resulting mixture was 
stirred at RT for 10 min, quenched with water (100 mL) and extracted with EtOAc. The 
organic layer was washed with water and brine, and dried with Na2SO4. After filtration and 
concentration of the filtrate in vacuo, the crude product was purified by chromatography, 
using EtOAc as eluent to obtain 107 (0.135 g, 79.8%) as orange crystals, mp 184-185 oC.   
 
1H NMR (200 MHz, DMSO-d6): δ = 2.67 (t, 2H, J = 6.4 Hz, SCH2CH2OH), 2.95
 (s,2H,NCH2CH2S), 3.58 (t, 2H, J = 6.5Hz, SCH2CH2OH), 4.82 (d, 2H, J = 4.5 Hz,
 NCH2CH2S-), 7.85 (s, 2H, H-7, H-8), 7,85 (s, 2H, H-4, H-9), 8.18 (s, 1H, H-6), 9.03 
 (s, 1H, H-3), 9.18 (d, 1H, H-1). 
13C NMR (50MHz, DMSO-d6): δ = 31.4 (-NCH2CH2S-), 34.6(-SCH2CH2OSi-), 45.1 (-
 NCH2CH2S-), 61.3 (-SCH2CH2OSi-), 112.8 (C-9), 118.3 (C-5a), 118.6 (C-4), 122.8 
 (C-6), 123.2 (C-5b), 134.8 (C-10a, C-4a), 139.3 (C-9a), 147.7 (C-1), 156.0 (C-3),
 177.9  (C-11), 179.4 (C-5). 
HRMS (M++1) calculated C19H17O3N2S 353.0960, found 353.0950. 
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IR (KBr disc) υmax: 3432, 2923, 2862, 2360, 1653, 1585, 1510, 1472, 1264 cm-1 
 
1.10 Synthesis of 10-(2-morpholinoethyl)-10H-pyrido[3,4-b]carbazole-5,11-dione (108) 
  
 
N
H
O
O
N
1. NaH/DMF
2.
O
N
Cl
.HCl N
O
O
N
N
O
93
10843.4 %
 
 
A solution of amine 93 (0.10 g, 0.41 mmol) in absolute DMF ( 5 mL) was added 
dropwise to a cooled (-5 to -10 oC) suspension of NaH (57 mg, 1.42 mmol, 60% in paraffin, 
washed twice with hexane) in DMF  (3 mL), after 30 min of stirring  4-(2-chloroethyl) 
morpholine hydrochloride (0.15 g, 0.84 mmol) in  DMF (5 mL) was added slowly and the 
reaction mixture was stirred at 69 oC for 4 h. After quenching with 50 mL of water the 
mixture was extracted several times with EtOAc and the combined organic phases were dried 
with Na2SO4. The solvent was removed by reduced pressure to give a crude product which 
was purified by column chromatography using 40% light petroleum/EtOAc to 5% 
MeOH/EtOAc  as eluent to obtain compound 108 (65 mg, 43.4%)  as red crystals, mp. 194-
195 oC. 
 
1H NMR (200 MHz, DMSO-d6): δ = 2.53 (s, 7H, overlapped with DMSO peak,-CH2OCH2- 
 morpholine ring), 2.73 (t, 2H, J = 6.4 Hz, NCH2CH2N-morpholine ing), 3.49 (t, 4H, J 
 = 4.4 Hz, -CH2NCH2- morpholine ring), 4.86 (t, 2H, J = 6.5 Hz, NCH2CH2N-
 morpholine), 7.46-7.57 (m, 2H, H-7, H-8), 7.85 (d, 1H, J =8.2 Hz, H-9),  7.95 (d, 1H, 
 J = 4.9 Hz, H-4), 8.27 (d, 1H, J = 7.7 Hz, H-6), 9.10 (d, 1H, J = 4.9 Hz, H-3), 9.26 (s, 
 1H, H-1). 
13C NMR (50 MHz, DMSO-d6): δ = 42.2 (NCH2CH2N-morpholine), 53.4 (NCH2CH2-
 morpholine), 57.4 (-CH2NCH2- morpholine ring), 66.2 (-CH2OCH2-morpholine), 
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 112.6 (C-9), 117.9 (C-5a), 118.3 (C-4), 122.4 (C-6), 122.9 (C-5b), 134.8 (C-10a), 
 139.0 (C-4a), 139.2 (C-9a), 147.4 (C-1), 155.7 (C-3), 177.7 (C-11), 179.2 (C-5). 
HRMS (M++1) calculated C21H20O3N3 362.1505, found 362.1498. 
IR (KBr disc) υmax: 2953, 2836, 1658, 1585, 1512, 1476, 1262, 1112 cm-1. 
 
1.11 Synthesis of 10-(2-pyrrolidineethyl)-10H-pyrido[3,4-b]carbazole-5,11-dione (109) 
 
 
93 109
O
N
N
H
O
1. NaH/ DMF
2.
N
Cl
.HCl
O
N
N
O
N
63.4 %
 
  
A solution of amine 93 (0.14 g, 0.58 mmol) in absolute DMF (5 mL) was added 
dropwise to a cooled (-5 to -10 oC) suspension of NaH (58 mg, 1.45 mmol, 60% in paraffin, 
washed twice with hexane) in DMF (3 mL). After 30 min of stirring 4-(2-
chloroethyl)pyrrolidine hydrochloride (0.147g, 0.87 mmol) in  DMF (5 mL) was added 
slowly and the reaction mixture was stirred at 69 oC for 2 h. After quenching with 50 mL of 
water the mixture was extracted several times with EtOAc and the combined organic phases 
were dried with Na2SO4. The solvent was removed by reduced pressure to give a crude pro-
duct which was purified by column chromatography using 40% light petroleum/EtOAc to 5% 
MeOH/EtOAc as eluent to obtain compound 109 (0.13 g, 63.4%) as yellow-green crystals, 
mp 180-181 oC. 
 
1H NMR (200 MHz, CDCl3): δ = 1.77-1.84 (m, 4H, -CH2CH2-pyrrolidine), 2.66 (d, 4H, J = 
 5.1 Hz, -CH2NCH2-pyrrolidine), 2.92 (t, 2H, J = 7.4 Hz, NCH2CH2N-pyrrolidine 
 ring), 4.87  (t, 2H, J = 7.4 Hz, NCH2CH2N-pyrrolidine), 7.37-7.57 (m, 3H, H-7, H-
 8, H-9), 7.99 (d, 1H, J = 4.9 Hz, H4), 8.42 (d, 1H, J = 7.5 Hz, H-6), 9.03 (d, 1H, J = 
 4.9 Hz, H-3), 9.38 (s, 1H, H-1). 
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13C NMR (50 MHz, CDCl3): δ = 23.6 (-CH2CH2-pyrrolidine), 44.5 (NCH2CH2-pyrrolidine),
 54.4 (-CH2NCH2-pyrrolidine), 55.3 (NCH2CH2N-pyrolidine), 111.2 (C-9), 118.6 (C-
 4), 119.1 (C-5a), 123.8 (C-6), 125.1 (C-7), 126.5 (C-11a), 127.9 (C-8) 134.5 (C-10a), 
 139.5 (C-4a,C-9a), 148.2 (C-1), 155.3 (C-3), 178.0 (C-11), 179.5 (C-5). 
HRMS (M++1) calculated C21H20O2N3 346.1556, found 346.1568. 
IR (KBr disc) υmax: 2926, 2795, 1661, 1585, 1478 cm-1. 
 
1.12 Synthesis of N-(2’-hydroxy ethyl)-2-oxazolidone (112) 
 
EtO OEt
O
O
N
O
OHH
N
OHHO +
NaOMe 
MeOH reflux
quantitative yield110 111 112
 
 
 To a solution of diethanolamine 110 (31.00 g, 29.4 mmol) and diethyl carbonate 111 
(44.0 mL, 36.3 mmol) was added NaOMe (0.14 g, 2.6 mmol) in one portion and the resulting 
mixture was refluxed for 2 h. Ethanol formed in the reaction was removed by distillation un-
der reduced pressure to give compound 112 in quantitative yield as colorless oil. The full 
characterization of compound 112 is in reference [54]. 
 
1H NMR (200 MHz, CDCl3): δ = 3.15 (t, 2H, J = 5.3 Hz), 3.47-3.55 (m, 4H), 4.14 (t, 2H, J = 
 2.6 Hz). 
 
 
1.13 Synthesis of N-(2’-chloroethyl)-2-oxazolidone (113) 
 
112
O
N
O
ClSOCl2 /CH2Cl2/DMF
84.2 %
O
N
O
OH
113
 
 
  To a solution of alcohol 112 (10.2g, 77.0 mmol) in dry CH2Cl2 was slowly added 
thionylchloride (6.2 mL, 85.4 mmol) and 2 drops of DMF. The mixture was continuously 
stirred at RT until the formed CO2 was completely gone. Saturated Na2CO3 (50 mL) was 
carefully added and the mixture was extracted with CH2Cl2. The combined organic layer we-
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re washed with water and dried with Na2SO4 and the solvent was evaporated to obtain 113 
(9.66g, 84.2 %) as a pale yellow oil. The full characterization of compound 113 is in referen-
ce [54]. 
 
1H NMR (200 MHz, CDCl3): δ = 3.46-3.69 (m, 6H), 4.29 (t, 2H, J = 8.3 Hz). 
 
1.14 Synthesis of 10-[(2-ethyl)-2-oxazolidone]-10H-pyrido[3,4-b]carbazole-5,11-dione 
(114) 
 
 
113
N
H
N
O
O
N
O
Cl
NaH / DMF 70 oC  6days
56.8% N
N
O
N
O
O
O O93
114
 
 
A solution of 93 (0.15 g, 0.62 mmol) in absolute DMF (5 mL) was added dropwise to 
a cooled (-5 to -10 oC) suspension of NaH (27mg, 0.67 mmol, 60% in paraffin, washed twice 
with hexane) in DMF (3 mL), after 30 min of stirring, a solution of compound 113 (0.14 g, 
0.94 mmol) in DMF (5 mL) was added slowly and the reaction mixture was stirred at 69 oC 
for 6 days. After quenching with 50 mL of water the mixture was extracted several times with 
EtOAc and the combined organic phases were dried with Na2SO4. The solvent was removed 
by reduced pressure to give a crude product which was purified by column chromatography, 
using EtOAc to 5% MeOH/EtOAc as eluent to obtain compound 114 (54 mg, 56.8%) as 
yellow solid, mp 230-231 oC. 
 
1H NMR (200 MHz, CDCl3): δ = 3.37 (t,2H, J = 8.2 Hz, -NCH2CH2O-), 3.76 (t, 2H  J = 6.3 
 Hz, -NCH2CH2N-oxazolidone), 4.11 (t, 2H, J = 7.5 Hz, -NCH2CH2O-), 4.93 (t, 2H, J 
 = 6.3 Hz, -NCH2CH2N-oxazolidone), 7.41-7.66 (m, 3H, H-7, H-8, H-9), 8.01 (d, 1H, J 
 = 4.9 Hz, H4), 8.43 (d, 1H, J = 8.0Hz, H-6), 9.05 (d, 1H, J = 4.9 Hz, H-3), 9.38 (s, 1H,  
 H-1). 
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13C NMR (50 MHz, CDCl3): δ = 43.1 (-NCH2CH2N-oxazolidone), 44.2 (-NCH2CH2N-
 oxazolidone), 45.7 (-NCH2CH2O-),  62.0 (-NCH2CH2O-) 111.0 (C-9), 118.7 (C-4), 
 119.7  (C-5a), 123.6 (C-5b), 123.9 (C-6) 125.5 (C-7), 126.3 (C-11a), 128.6 (C-8) 
 133.3 (C-10a), 139.5 (C-4a), 139.9 (C-9a), 148.2 (C-1), 155.8 (C-3), 158.4 (C=O, 
 oxazolidone), 178.0  (C-11), 179.5 (C-5). 
HRMS (M++1) calculated C21H18O4N3 362.1107, found 362.1133. 
IR (KBr disc) υmax: 2956, 2922, 1744, 1653, 1585, 1468, 1260 cm-1. 
 
1.15 Synthesis of 10-(2-chloroethyl)-10H-pyrido[3,4-b]carbazole-5,11-dione (116) 
 
93
N
H
N
O
O
1. NaH/DMF
2.
Br Cl N
N
O
O
Cl
85.1 % 116
 
 
A solution of 93 (0.15 g, 0.61 mmol) in absolute DMF (5 mL) was added dropwise to 
a cooled (-5 to -10 oC) suspension of NaH (27 mg, 0.67 mmol, 60% in paraffin, washed twice 
with hexane) in DMF  (3 mL), after 30 min of stirring a solution of 1-bromo-2-chloroethane 
(0.10 mL, 0.122 mmol) in  DMF (5 mL) was added slowly and the reaction mixture was 
stirred at 69 oC for 3 h. After quenching with 50 mL of water the mixture was extracted 
several times with EtOAc and the combined organic phases were dried with Na2SO4. The 
solvent was removed by reduced pressure to give a crude product which was purified by 
column chromatography using 40% EtOAc/light petroleum as eluent to obtain compound 116 
(0.16 g, 85.1%) as orange crystals, mp 193-194 oC. 
 
1H NMR (200 MHz, DMSO-d6): δ = 4.08 (t, 2H, J = 5.8 Hz, NCH2CH2Cl), 5.06 (t, 2H  J = 
 5.8 Hz, NCH2CH2Cl), 7.39-7.57 (m, 2H, H-7, H-8), 7.90 (t, 2H, J = 4.4 Hz, H-4, 
 H-9), 8.24 (d, 1H, J = 7.5 Hz, H6), 9.06 (d, 1H, J = 4.8 Hz, H-3), 9.22 (s, 1H, H- 1). 
13C NMR (50 MHz, DMSO-d6): δ = 43.0 (NCH2CH2Cl), 46.0 (NCH2CH2Cl), 112.8 (C-
 9),118.0 (C-4), 118.3(C-5a), 122.3 (C-6), 122.6 (C-5b), 125.0 (C-7), 126.2 (C-11a), 
 127.6 (C-8),  134.7 (C-10a), 138.6 (C-4a), 139.5 (C-9a), 147.4 (C-1), 155.7 (C-3), 
 177.6 (C-11), 179.3 (C-5). 
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MS m/e (% relative intensity): M+ 310(28.8), 283(22.6), 275(100), 261(58.2), 248(19.8),
 220(21.8), 191(17.6), 177(8.7), 164(24.3), 151(11.3), 137(22.0), 137(22.0), 114(14.5),
 101(7.5), 88(14.1), 63(15.0), 50(19.2). 
IR (KBr disc) υmax: 3044, 2923, 2852, 1660, 1584, 1511, 1471, 754 cm-1. 
 
 
1.16 Synthesis of 3-(4-methylpiperazin-1-yl)-10-vinyl-10H-pyrido[3,4-b]                  car-
bazole-5,11-dione (119) 
 
116
N N
O
O
1. NaH / DMF
69 oC   2 days  18.2 %
N N
O
O
N
N
Cl
2.N
H
N
118 119
 
 
A solution of amine 118 (0.10 mL, 0.90 mmol) in absolute DMF (5 mL) was added 
dropwise to a cooled (-5 to -10 oC) suspension of NaH (27 mg, 0.67 mmol, 60% in paraffin, 
washed twice with hexane) in DMF (3 mL), after 30 min of stirring 116 ( 94 mg, 0.30mmol) 
in DMF (5 mL) was added slowly and the reaction mixture was stirred at 69 oC for 2 days. 
After quenching with 50 mL of water the mixture was extracted several times with EtOAc 
and the combined organic phases were dried with Na2SO4. The solvent was removed by 
reduced pressure to give the crude product which was purified by column chromatography, 
using EtOAc to 5% MeOH/EtOAc as eluent to obtain compound 119 (21mg, 18.2%) as red 
crystals, mp. 199-200 oC. 
 
1H NMR (500 MHz, CDCl3): δ = 2.36 (s, 3H, NCH3), 2.54 (m, 4H, (CH3)NCH2)2-
 piperazine), 3.87 (m, 4H, (-N(CH2)2-piperazine), 5.54 (dd,1H, J = 0.9, 8.8 Hz, 
 CH2=CH), 5.66 (dd, 1H, J = 0.9, 15.9 Hz) 7.24 (s, 1H, H-4), 7.40 (d, 1H, J = 5.0 Hz, 
 H-7)  7.44 (d, 1H, J = 5.0 Hz, H-8), 7.76 (d, 1H, J = 8.8 Hz, H-9), 7.85 (dd, 1H, J = 
 8.8, 15.9 Hz, CH2=CH), 8.40  (d, 1H, J = 5.0 Hz, H-6), 8.88 (s, 1H, H-1). 
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13C NMR (125 MHz, CDCl3): δ = 44.8 (-N(CH2)2-piperazine), 46.1 (NCH3), 54.7 ((CH3)N 
 CH2)2- piperazine), 101.5 (C-4), 110.8 (CH2=CH), 112.9 (C-9), 116.9(C-11a), 119.1 
 (C-5a), 123.6 (C-6), 124.9 (C-7), 127.7 (C-8), 131.6 (CH2=CH), 137.8 (C-9a), 141.2 
 (C-4a), 149.8 (C-1), 161.1 (C-3), 176.8 (C-11), 180.6 (C5). 
HRMS (M++1) calculated C22H21O2N4 373.1665, found 373.1673. 
IR (KBr disc) υmax: 2963, 2925, 2854, 2793, 1659, 1595, 1518, 145, 1285 cm-1. 
 
1.17 Synthesis of 3-(4-methylpiperrazin-1-yl)-10-vinyl-10H-pyrido[3,4-b]                car-
bazole-5,11-dione (119) 
 
116
KI / K2CO3 /DMF 
   1-methylpiperazine
69 OC  5 days
16.0 %
N N
O
O
N N
O
O
N
N
Cl
119
 
 
K2CO3 (65 mg, 0.69 mmol), KI (85 mg, 0.51 mmol) and 1-methypeperazine (0.08 
mL, 0.36 mmol) were added to a solution of compound 116 (0.105g, 0.33 mmol) in dry DMF 
(6 mL). The mixture was stirred for 5 days at 69 oC, poured into water (50mL) and extract 
with EtOAc. The organic layer was washed with brine, dried with Na2SO4 and evaporated. 
The residue was purified by chromatography, using EtOAc to 5% MeOH/EtOAc as eluent to 
obtain compound 119 (20 mg, 16.1%) as red crystals, mp 199-200 oC. 
 
1H NMR (500 MHz, CDCl3): δ = 2.36 (s, 3H, NCH3), 2.54 (m, 4H, CH3N(CH2)2-piperazine),
 3.87 (m, 4H, -N(CH2)2-piperazine), 5.54 (dd,1H, J = 0.9, 8.8 Hz, CH2=CH), 5.66 (dd, 
 1H, J = 0.9, 15.9 Hz) 7.24 (s, 1H, H-4), 7.40 (d, 1H, J = 5.0 Hz, H-7)  7.44 (d, 1H, J =
  5.0 Hz, H-8), 7.76 (d, 1H, J = 8.8 Hz, H-9), 7.85 (dd, 1H, J = 8.8, 15.9 Hz, CH2=CH), 
 8.40 (d, 1H, J = 5.0 Hz, H-6), 8.88 (s, 1H, H-1). 
13C NMR (125MHz, CDCl3): δ =  44.8 (-N(CH2)2-piperazine), 46.1 (NCH3), 54.7 CH3)N 
 CH2)2- piperazine), 101.5 (C-4), 110.8 (CH2=CH), 112.9 (C-9), 116.9(C-11a), 119.1 
 (C-5a), 123.6 (C-6), 124.9 (C-7), 127.7 (C-8), 131.6 (CH2=CH), 137.8 (C-9a), 141.2 
 (C-4a), 149.8 (C-1), 161.1 (C-3), 176.8 (C-11), 180.6 (C5). 
HRMS (M++1) calculated C22H21O2N4 373.1665, found 373.1673. 
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IR (KBr disc) υmax: 2963, 2925, 2854, 2793, 1659, 1595, 1518, 145, 1285 cm-1. 
 
1.18 Synthesis of 10-(2-iodoethyl)-10H-pyrido[3,4-b]carbazole-5,11-(10H)-dione (117) 
 
116
N N
O
O
Cl
N N
O
O
I
NaI/ acetone
reflux 5 days
99.4 %
117
 
 
To a solution of compound 116 (0.25 g, 0.81 mmol) in acetone (30 mL) was added 
NaI (1.22 g, 8.14 mmol) in one portion and the resulting mixture was refluxed for 5 days. 
After cooling down to RT, acetone was removed by distillation under reduced pressure to 
give a crude product which was purified by column chromatography, using 40% EtOAc/ light 
petroleum as eluent to obtain compound 117 (0.325g, 99.4%)  as orange crystals, mp 209-210 
oC. 
 
1H NMR (200 MHz, DMSO-d6): δ = 3.58 (t, 2H, J = 7.2 Hz, NCH2CH2I), 5.04 (t, 2H  J = 7.2 
 Hz, NCH2CH2I), 7.39-7.57 (m, 2H, H-7, H-8), 7.88 (t, 2H, J = 4.9 Hz, H-4, H-9), 8.22 
 (d, 1H, J = 7.7 Hz, H6), 9.06 (d, 1H, J = 4.9 Hz, H-3), 9.21 (s, 1H, H-1). 
13C NMR (50 MHz, DMSO-d6): δ = 2.5 (NCH2CH2I), 46.4 (NCH2CH2I), 112.6 (C-9),118.1 
 (C-5a), 118.3 (C-4) 122.4 (C-6), 122.8 (C-5b), 125.1 (C-7), 126.2 (C-11a), 127.6 (C-
 8) 134.3 (C-10a), 138.7 (C-4a), 138.8 (C-9a), 147.4 (C-1), 155.7 (C-3), 177.6 (C-11), 
 179.3 (C-5). 
MS m/e (% relative intensity): M+ 402(8.7), 275(100), 261(14.8), 219(14.1), 191(16.3),
 164(23.2), 137(19.8), 50(28.2). 
IR (KBr disc) υmax: 3041, 2924, 1653, 1584, 1511, 1472 cm-1. 
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1.19 Synthesis of 10-[4-(1-methypeperazine)]-10H-pyrido[3,4-b]carbazole-5,11-dione 
(120) 
 
117
N N
O
O
N
N
N N
O
O
I
EtOH/THF
5 days 56.8%
N
H
N
120
118
 
 
 1-Methylpiperazine 118 (0.69 mL, 6.3 mmol) was added into the solution of 
compound 117 (0.126g, 0.31 mmol) in ethanol (10 mL) and THF (2 mL) in a sealed tube. 
The mixture was heated for 7 days at 75 oC.  After the solvent was evaporated, the residue 
was purified by column chromatography, using EtOAc to 10% MeOH/EtOAc as eluent to 
obtain compound 120 (67 mg, 56.8%) as orange crystals, mp 163-164 oC. 
 
1H NMR (200 MHz, CDCl3): δ = 2.24 (s, 3H, -NCH3), 2.39 (s, 4H, CH3N(CH2)2-piperazine) 
 2.61 (s, 4H, -CH2N(CH2)2-piperazine), 2.77 (t, 2H, J = 7.0 Hz)4.83 (t, 2H, J = 6.9), 
 7.40-7.49 (m, 3H, H-7, H-8, H-9), 7.97 (d, 1H, J = 4.9 Hz, H4), 8.40 (d, 1H, J = 7.3 
 Hz, H-6), 9.01 (d, 1H, J = 4.9 Hz, H-3), 9.35 (s, 1H, H-1). 
13C NMR (50MHz, CDCl3): δ = 43.0 (-NCH2CH2N-), 45.9 (-NCH3), 53.3 (CH3N(CH2)2-
 piperazine), 55.0 (-N(CH2)2-piperazine), 57.2 (-NCH2CH2N-), 111.2 (C-9), 118.6 
 (C-4),  119.1 (C-5a), 123.8 (C-6), 124.3 (C-5b), 125.0 (C-7), 126.5 (C-11a), 127.7 (C-
 8), 134.6 (C-10a), 139.4 (C-4a, C-9a), 148.2 (C-1), 155.5 (C-3), 178.1 (C-11), 179.5 
 (C-5). 
HRMS (M++1) calculated C22H23O2N4 375.1821, found 375.1671. 
IR (KBr disc) υmax: 2963, 2925, 2854, 2793, 1659, 1595, 1518, 145, 1285 cm-1. 
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1.20 Synthesis of tert-butyl-[2-(methylamino)ethanol]-diphenylsilane (122) 
 
 
H
N
O
Si
PhH
N
OH
Si
Ph
Ph
Cl
quantitative yield
Ph
121
122
 
 
 To solution of tert-butyldiphenylchlorosilane (8.0 mL, 31.2 mmol) in  CH2Cl2 (10 
mL) was added dropwise to a solution of 2-(methylamino)ethanol 121 (2.5 mL, 31.2 mmol) 
in CH2Cl2 (34 mL) and allowed cool at 0 oC for 1 h. Then the mixture was warm up to RT 
and continuously stirred for 2 h. Then the water was added and the mixture was extracted 
with EtOAc. The combined organic layers were washed with water and dried with Na2SO4 
and the solvent was evaporated to give compound 122 in quantitative yield as colorless oil. 
 
1H NMR (200 MHz, CDCl3): δ = 1.06 (s, 9H, C(CH3)3), 2.49 (s, 3H, NCH3), 2.77 (t, 2H, J 
 =5.3 Hz,NHCH2CH2O), 3.53 (s, 1H, NH), 3.81 (t, 2H, J = 5.1 Hz, NHCH2CH2O), 
 7.37-7.41 (m, 6H, Ph), 7.64-7.68 (m, 4H, Ph). 
13C NMR (50 MHz, CDCl3): δ = 19.0 (C(CH3)3), 26.6 (C(CH3)3), 35.7 (NCH3), 53.0
 (NHCH2CH2O), 62.3 (NHCH2CH2O), 127.5 (Ph), 129.5 (Ph), 133.2 (Ph), 135.3 (Ph). 
MS m/e (% relative intensity): 256(100), 211(4.4), 199(18.6), 183(11.9), 178(49.3), 
 105(15.3), 77(11.0), 44(84.5).  
IR (NaCl disc) υmax: 3471, 3049, 2931, 2790, 2460, 1589, 1471, 1427, 1103, 947,705 cm-1. 
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1.21 Synthesis of 10-(2-((2-(tert-butyldiphenylsilyloxy)ethyl)(methyl)amino)ethyl)                 
-10H-pyrido[3,4-b]carbazol-5,11-dione (123) 
 
123
N N
O
O
I
N N
O
O
N
O
EtOH/THF 70 oC
5 days 33.5%
SiPh Ph
H
N
O
Si
Ph
Ph
117
122
 
 
Compound 122 (0.93 g, 2.98 mmol) was added into the solution of compound 117 
(0.12g, 0.29 mmol) in ethanol (10 mL) and THF (2 mL) in a sealed tube. The mixture was 
heated for 6 days at 70 oC.  After the solvent was evaporated, the residue was purified by 
column chromatography, using 40% EtOAc/light petroleum as eluent to afford compound 
123 (57 mg, 33.5%) as orange crystals, mp 65-66 oC. 
 
1H NMR (200 MHz, CDCl3): δ = 0.99 (s, 9H, C(CH3)3),  2.39 (s,3H, NCH3), 2.67 (t, 2H, 
 J = 6.2 Hz, NCH2CH2O), 2.85 (t, 2H, J = 7.2 Hz, NCH2CH2N), 3.64 (t, 2H, J =  6.2 
 Hz, NCH2CH2O), 4.77 ( t, 2H, J = 6.9 Hz, NCH2CH2N), 7.32-7.44 (m, 9H), 7.59-7.63 
 (m, 4H), 7.89 (d, 1H, J = 4.8 Hz), 9.02 (d, 1H, J = 4.9 Hz), 9.35 (s, 1H). 
13C NMR (50MHz, CDCl3): δ = 19.0 (C(CH3)3), 26.7 (C(CH3)3), 43.3(NCH3) 43.7 
 (NCH2CH2O-) 57.2 (NCH2CH2N), 59.5 (-NCH2CH2N), 62.3 (NCH2CH2O), 111.3 (C-
 9), 118.6 (C-4), 119.0 (C-5a), 123.0 (C-5b), 123.7 (C-6), 125.0 (C-7), 126.5 (C-11a), 
 127.6 (Ph), 127.7 (C-8), 129.6 (Ph), 133.5 (Ph), 134.4 (C-10a), 135.5 (Ph), 139.5 (C-
 4a, C-9a), 148.3 (C-1), 155.4 (C-3), 178.0 (C-11), 179.5 (C-5). 
HRMS (M++1) calculated C36H38O3N3Si 588.2682, found 588.2683. 
IR (KBr disc) υmax: 3070, 2928, 2855, 1663, 1585, 1509, 1472, 1112, 748, 703 cm-1. 
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1.22 Synthesis of 10-(2-((2-hydroxylethyl)(methyl)amino)ethyl)-10H-pyrido[3,4-
b]carbazol-5,11-dione (124) 
 
123 124
N N
O
O
N
O
Bu4N
+ - F
THF 1 hour
23.4 %
N N
O
O
N
OH
SiPh Ph
 
 
A solution of 1M Bu4NF (0.4 mL, 0.4 mmol) in THF was added to the solution of 
compound 123 (92 mg, 0.15 mmol) in absolute THF (10 mL) and the resulting mixture was 
stirred at RT for 1 h, quenched with water (100 mL) and extracted with EtOAc. The organic 
layer was washed with water and brine, and dried with Na2SO4. After filtration and 
concentration of the filtrate in vacuo, the crude product was purified by chromatography, 
using 10% MeOH/CH2Cl2 as eluent to obtain 124 (11 mg, 23.4%) as red crystals, mp.102-103 
oC. 
 
1H NMR (200 MHz, CDCl3): δ = 2.44 (s,3H, NCH3), 2.64 (t, 2H, J = 5.3 Hz, NCH2CH2O), 
 2.91 (t, 2H, J = 7.0 Hz, NCH2CH2N), 3.50 (t, 2H, J = 5.2 Hz, NCH2CH2O), 4.81 ( t, 
 2H, J = 6.8Hz, NCH2CH2N), 7.41 (dd, 1H, J = 4.0, 7.8Hz, H-8), 7.48 (m, 2H, H-7, H-
 9), 7.95 (d, 1H, J = 4.9 Hz, H-4), 8.39 ( d, 1H, J = 7.7 Hz, H-6), 9.01 (d, 1H, J = 4.9 
 Hz, H-3), 9.35 (s, 1H, H-1).  
13C NMR (50 MHz, CDCl3): δ = 42.1 (NCH3) 43.4 (NCH2CH2O-), 56.9 (NCH2CH2N), 58.5 
 (-NCH2CH2N), 59.1(NCH2CH2O), 111.3 (C-9), 118.6 (C-4), 119.2 (C-5a), 123.6 (C-
 5b), 123.9 (C-6), 125.1 (C-7), 126.4 (C-11a), 128.0 (C-8), 134.1 (C-10a), 139.4 (C- 
 4a), 139.5 (C-9a), 148.2 (C-1), 155.5 (C-3), 178.1 (C-11), 179.4 (C-5). 
HRMS (M++1) calculated C20H20O3N3 350.1505 found, 350.1503. 
IR (KBr disc) υmax: 3422, 2942, 2850, 1758, 1585, 1514, 1476, 1260 cm-1. 
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1.23 Synthesis of 10-(2-((2-hydroxylethyl)(methyl)amino)ethyl)-10H-pyrido[3,4-
b]carbazol-5,11-dione (124) 
 
124
N N
O
O
I
N N
O
O
N
OH
H
N
OH
EtOH/THF 70 oC
5 days 36.3%
117
121
 
 
 Amine 121 (0.27 mL, 3.30 mmol) was added into the solution of compound 117 (69 
mg, 0.17 mmol) in ethanol (10 mL) and THF (2 mL) in sealed tube. The mixture was heated 
for 5 days at 70 oC. After the solvent was evaporated, the residue was purified by column 
chromatography, using 10% MeOH/CH2Cl2 as eluent to obtain compound 124 (19 mg, 
36.3%) as red crystals, mp 102-103 oC. 
 
1H NMR (200 MHz, CDCl3): δ = 2.44 (s,3H, NCH3), 2.64 (t, 2H, J = 5.3 Hz, NCH2CH2O),
 2.91 (t, 2H, J = 7.0 Hz, NCH2CH2N), 3.50 (t, 2H, J = 5.2 Hz, -NCH2CH2O), 4.81 ( t, 
 2H, J = 6.8 Hz, NCH2CH2N), 7.41 (dd, 1H, J = 4.0, 7.8 Hz, H-8), 7.48 (m, 2H, H-7, 
 H-9), 7.95 (d,1H, J = 4.9 Hz, H-4), 8.39 ( d, 1H, J = 7.7 Hz, H-6), 9.01 (d, 1H, J = 4.9 
 Hz, H-3), 9.35 (s, 1H, H-1). 
13C NMR (50 MHz, CDCl3): δ = 42.1 (NCH3) 43.4 (NCH2CH2O-), 56.9 (NCH2CH2N), 58.5 
 (-NCH2CH2N), 59.1 (NCH2CH2O), 111.3 (C-9), 118.6 (C-4), 119.2 (C-5a), 123.6 (C-
 5b), 123.9 (C-6), 125.1 (C-7), 126.4 (C-11a), 128.0 (C-8), 134.1(C-10a), 139.4 (C-
 4a), 139.5(C-9a), 148.2 (C-1), 155.5 (C-3), 178.1 (C-11), 179.4 (C-5). 
HRMS (M++1) calculated C20H20O3N3 350.1505 found, 350.1503. 
IR (KBr disc) υmax: 3422, 2942, 2850, 1758, 1585, 1514, 1476, 1260 cm-1 
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2. Synthesis of benzo[a]fluorine-5,6-dione derivatives 
 
2.1 Synthesis of 6,7-dichloro-5,8-isoquinolinedione (126) 
 
125 126
N
O
O
Cl
Cl
N
OH
HCl / HNO3
80 - 90 oC 1 hr,
    11.0 %
 
 
Concentrated HNO3 (10 mL) was added in portions over 30 minutes to a stirred sus-
pension of 5-hydroxyisoquinoline 125 (11.00 g, 75 mmol) in concentrated HCl (190 mL) at 
80-90 oC. The resulting mixture was diluted to 2 L by ice water and extracted with ether. The 
organic phases were combined, extracted with water and dried over Na2SO4. After filtration 
and concentration of the filtrate in vacuo, the crude product was purified by column 
chromatography, using 1:1 ether:light petroleum as eluent to afforded 126 (1.45 g, 8.44%) as 
pale-green crystals, mp. 180-181 oC. The full characterization of compound 126 is in referen-
ce [57]. 
 
2.2 Synthesis of 5-chloropyrido[1’,2’-1,2]imidazo[4,5-f]isoquinoline-5,6-dione (128a) and 
5-chloropyrido[1’,2’-2,3]imidazo[4,5-f]isoquinoline-5,6-dione (128b) 
N NH2
Cl
N
O
O
N
N
N
O
O
N
N
Cl
Cl
+
K2CO3/ EtOH
85 oC 5 hr.
N
O
O
Cl
Cl
126
127
128a
128b
27.9 %
9.8 %
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 K2CO3 (0.27 g, 2.2 mmol) and 2-amino-5-chloropyridine 127 (0.37 g, 2.9 mmol) were 
added to a solution of quinone 126 (0.50g, 2.2 mmol) in ethanol (25 mL). The resulting 
mixture was refluxed for 5 h then cooled down to RT. The solvent was evaporated and the 
residue was extracted several times with CH2Cl2. The combined organic phases were washed 
with water and dried with Na2SO4, concentrated and then the residue was purified by column 
chromatography, using EtOAc: light petroleum: MeOH (4:4:1) as eluent to afford 128a (0.17 
g, 27.9%) and 128b (6 mg, 9.8 %) as yellow crystals, mps: 309-310 oC and 251-253 oC, 
respectively. 
 
128a: mp 309-310 oC. 
 
1H NMR (500 MHz, CDCl3): δ = 7.88 (dd, 1H, J = 2.1, 9.5 Hz, H-10), 8.02 (d, 1H, J = 5.0 
 Hz, H-1), 8.05 (d, 1H, J = 9.5 Hz, H-11), 8.92 (d, 1H, J = 5.1 Hz, H-2), 9.07 (s, 1H, 
 H-4), 9.24 (m, 1H, J = 2.1 Hz, H-8). 
13C NMR (125 MHz, CDCl3): δ = 117.5 (C-1), 119.1 (C-11), 121.8 (C-6a), 124.2 (C-9), 
 125.0 (C-4a), 125.8 (C-8), 132.9 (C-10), 137.5 (C-12b), 147.4 (C-11a), 149.4 (C-4), 
 149.7 (C-12a), 155.4 (C-2), 167.0 (C-6), 180.3 (C-5). 
MS m/e (% relative intensity): M+ 283(22.7), 255 (100), 227(16.0), 220(8.4), 192(22.8), 
 165(17.1), 138(7.9), 114(23.8), 100(15.7), 88(27.0), 76(45.0), 57(27.6), 43(24.6). 
IR (KBr disc) υmax: 3101, 2923, 2852, 1700, 1651, 1595, 1487, 1408, 821 cm-1. 
 
128b: mp 251-253 oC. 
 
1H NMR (500 MHz, DMSO-d6): δ = 7.84 (dd, 1H, J = 5.1 Hz, H-4), 7.91 (S, 1H), 8.06 (d,1H, 
 J = 9.5 Hz, H-11), 8.88 (d, 1H, J = 5.0 Hz, H-3),  (d, 1H, J = 5.1 Hz, H-2), 9.24 (s, 1H, 
 H-8),  9.31 (s, 1H, H-1). 
13C NMR (125 MHz, DMSO-d6):δ = 118.9 (C-11), 120.7 (C-4), 121.4 (C-6a), 124.8 (C-9), 
 125.8 (C-8), 132.9 (C-10), 145.3 (C-1), 152.7 (C-6), 180.1 (C-5). 
MS m/e (% relative intensity): M+ 283(22.7), 255 (100), 227(16.0), 220(8.4), 192(22.8),
 165(17.1), 138(7.9), 114(23.8), 100(15.7), 88(27.0), 76(45.0), 57(27.6), 43(24.6). 
IR (KBr disc) υmax: 3035, 2923, 1706, 1649, 1494, 1247, 832 cm-1. 
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2.3. Synthesis of 5-bromopyrido[1’,2’-1,2]imidazo[4,5-f]isoquinoline-5,6-dione (134a) 
and 5-bromopyrido[1’,2’-2,3]imidazo[4,5-f]isoquinoline-5,6-dione (134b) 
 
K2CO3/ EtOH
85 oC 5 hr.
N
O
O
Cl
Cl
126
133
N NH2
Br
N
O
O
N
N
N
O
O
N
N
Br
+
Br
134a
134b
9.2 %
4.3 %
 
 
K2CO3 (0.32 g, 2.3 mmol) and 2-amino-5-bromopyridine 133 (0.50 g, 2.9 mmol) were 
added to a solution of quinone 126 (0.52 g, 2.3 mmol) in ethanol (25 mL). The resulting 
mixture was refluxed for 5 h then cooled down to RT. The solvent was evaporated and 
extracted with CH2Cl2 several times. The combined organic phases were washed with water 
and dried with Na2SO4, concentrated and then the residue was purified by column 
chromatography, using EtOAc: light petroleum: MeOH (4:4:1) as eluent to afford 134a 
(69mg, 9.2%) as red-brown crystals and compound 134b (32 mg, 4.3%) as red crystals, mps: 
249-250 oC and 309-310 oC, respectively. 
 
134a: mp 249-250 oC. 
 
1H NMR (500 MHz, DMSO-d6): δ = 7.89 (s, 1H, H-10), 8.00 (s, 1H, H-11), 8.03 (s, 1H, H-
 1), 8.92 (s, 1H, H-2), 9.06 (s, 1H, H-4), 9.29 (s, 1H, H-8). 
13C NMR (125 MHz, DMSO-d6): δ = 111.4 (C-9), 117.5 (C-1), 119.3 (C-11), 121.8 (C-6a) 
 125.1 (C-4a), 127.8 (C-8), 133.4 (C-10), 137.6 (C-12b), 147.6 (C-11a), 149.4 (C-4, 
 C12a), 155.6 (C-2), 167.3 (C-6), 180.3 (C-5). 
MS m/e (% relative intensity): M+ 312(100), 312(4.7), 299(16.2), 267(6.8), 218(14.3), 
 191(10.4), 177(5.3), 156(30.8), 88(20.8), 76(85.9), 63(19.7), 43(20.2). 
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IR (KBr disc) υmax: 3029, 2923, 2853, 1706, 1646, 1604, 1492, 1249 cm-1. 
 
134b: mp 309-310 oC. 
 
1H NMR (500 MHz, DMSO-d6): δ = 7.83 (d, 1H, J = 5.0 Hz), 8.88 (d, 1H, J = 5.0 Hz), 9.30 
 (s, 1H). 
13C NMR (125MHz, DMSO-d6): δ = 120.8 (C-4), 128.8 (C-8), 145.3 (C-1), 152.8 (C-3), 
 167.2 (C-6), 180.1 (C-5). 
MS m/e (% relative intensity): M+ 312(100), 312(4.7), 299(16.2), 267(6.8), 218(14.3), 
 191(10.4), 177(5.3), 156(30.8), 88(20.8), 76(85.9), 63(19.7), 43(20.2). 
IR (KBr disc) υmax: 3015, 2923, 2853, 1691, 1641, 1603, 1409, 1251 cm-1. 
 
2.4 Synthesis of 5-nitropyrido[1’,2’-1,2]imidazo[4,5-f]isoquinoline-5,6-dione (136a) 
 
 
N NH2
N
O
O
N
N
NO2
CeCl3 .7H2O / EtOH
reflux 3 days 2.0%
N
O
O
Cl
Cl
126
135
136aO2N
 
 
CeCl3.7H2O (0.63 g, 1.7 mmol) and 2-amino-5-nitropyridine 135 (0.23 g, 1.7 mmol) 
were added to a solution of quinone 126 (0.39g, 1.7 mmol) in ethanol (25 mL). The resulting 
mixture was refluxed for 3 days then cooled down to RT. The solvent was evaporated and 
extracted with CH2Cl2 several times. The combined organic phases were washed with water 
and dried with Na2SO4, concentrated and then the residue was purified by column 
chromatography, using EtOAc:light petroleum:MeOH (4:4:1)  as eluent to afford 136a (40 
mg, 2.0%) as yellow crystals, mp 144-145 oC. 
 
1H NMR (500 MHz, DMSO-d6): δ = 8.07 (s, 1H), 8.19 (d, 1H, J = 9.9 Hz), 8.46 (dd,1H, J = 
 2.3, 9.9 Hz), 8.97 (d, 1H, J = 4.9 Hz), 9.11 (s, 1H), 9.94 (dd, 1H, J = 2.3 Hz). 
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13C NMR (125MHz, DMSO-d6): δ = 117.7 (C-1), 118.0 (C-11), 122.8 (C-6a), 125.4 (C-4a), 
 125.8 (C-10), 127.1 (C-8), 137.0 (C-12b), 139.6 (C-9), 149.1 (C-11a), 149.4 (C-4), 
 151.5  (C-12a), 155.6 (C-2), 167.7 (C-6), 179.6 (C-5). 
MS m/e (% relative intensity): M+ 249(24.2), 221(100), 193(26.9), 166(10.8),139(7.1), 
 88(11.5), 78(14.5), 51(16.0). 
IR (KBr disc) υmax: 3048, 2923, 2852, 1647, 1550, 1305 cm-1. 
 
2.5  Synthesis of 5-chloropyrido[1’,2’-1,2]imidazo[4,5-f]-2-((2-
(dimethylamino)ethyl)methylamino)isoquinoline-5,6-dione (138b) 
 
 
N
O
O
N
N
Cl
H
N
N
THF/EtOH 85 oC
N
O
O
N
N
Cl
N
N
128a 138b
60.0 %
137
 
 
 
 N,N,N’-trimethylethylenediamine 137 (0.05 mL, 0.3 mmol) was added to a solution 
of compound 128a (25 mg, 0.08 mmol) in ethanol (8 mL) and THF (2 mL) in a sealed tube. 
The mixture was heated for 5 h at 85 oC.  After the solvent was evaporated, the residue was 
purified by column chromatography, using 10% MeOH/EtOAc
 
as eluent to obtain (18 mg, 
60.0%) 138b as red solid, mp 230-231 oC. 
 
1H NMR (500 MHz, CDCl3): δ = 2.34 (s, 6H, N(CH3)2), 2.62 (t, 2H, J = 6.9 
 Hz,(CH3)2NCH2), 3.31 (s, 3H, NCH3), 3.92 (s, brs, 2H, (CH3)2NCH2CH2), 7.18 (s,1H, 
 H-1), 7.58 (d, 1H, J =  9.5 Hz, H-10), 7.75 (d, 1H, J = 9.5 Hz, H-11), 8.90 (s, 1H, H-
 4), 9.37 (s, 1H, H-8). 
13C NMR (125 MHz, CDCl3): δ = 37.3 (NCH3), 45.6 (N(CH3)2), 48.3 (CH3)2NCH2CH2), 56.7
 (CH3)2NCH2), 99.7 (C-1), 114.7 (C-4a), 118.3 (C-11), 121.7 (C-6a), 124.8 (C-9), 
 126.6 (C-8), 132.7 (C-10), 138.1 (C-12b), 147.8 (C-11a), 151.3 (C-12a), 159.8 (C-4), 
 160.9  (C-2), 170.1 (C-6), 178.4 (C-5). 
HRMS (M++1) calculated C19H19O2ClN2 384.1227 found 384.1225. 
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IR (KBr disc) υmax: 2924, 2853, 1649, 1600, 1540, 730 cm-1. 
 
2.6 Synthesis of 5,8-dimethoxyquinazoline (140) 
 
 
NHCHO
NHCHO
NO2
OCH3
OCH3
Zn/glacial acetic acid
N
N
OCH3
OCH3
139 140
 
 
 To a suspension of compound 139 (21.70 g, 76.6 mmol) in ice (210 g), glacial acetic 
acid (102 mL) and Zn metal (69.0g) were added in small portions during 1 h while the 
reaction mixture was vigorously stirred in an ice bath. The resulting mixture then was 
warmed to RT, and additional Zn (19.0 g) was added in small portions. Stirring was 
continued for a further 1.5 h. The reaction mixture was filtered into a solution of 50% NaOH 
(480 mL). The yellow suspension was extracted with ether. The combined organic phases 
were washed with water, dried with Na2SO4 and evaporated to give a light yellow solid which 
was used without purification for the next step. The full characterization of compound 140 is 
in reference [57]. 
 
2.7 Synthesis of 6,7-dichloro-5,8-quinazolinedione (141) 
 
140
N
N
OCH3
OCH3
N
N
O
O
Cl
Cl
HNO3/H2SO4
141
4.7%
 
 
Concentrated HNO3 (5 mL) was added in portions over 15 min to a stirred solution of 
compound 140 (7.60g, 40 mmol) in concentrated HCl (100 mL) at 80-90 oC. The solution 
mixture was cooled to RT and diluted with water (1L) and extracted with ether. The 
combined organic layers were washed with water and brine and dried with Na2SO4.  After, 
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filtration and concentration of the filtrate in vacuo, the crude product was purified by 
chromatography, using 1:1 ether: light petroleum as eluent to give 141 (1.73 g, 4.76%) as 
pale-yellow, mp 135-136 oC crystals. The full characterization of compound 141 is in refe-
rence [57]. 
 
2.8 Synthesis of pyrido[1’,2’-1,2]imido[4,5-f]quinazoline-5,6-dione (143a) 
 
141
N
N
O
O
Cl
Cl
N NH2
K2CO3/EtOH
N
N
N
N
O
O
142
143a
 
 
K2CO3 (60 mg, 0.4 mmol) and 2-aminopyridine 142 (49 mg, 0.5 mmol) were added to 
a solution of quinone 141 (99 mg, 0.4 mmol) in ethanol 20 mL. The resulting mixture was 
refluxed for 4 h, then cooled down to RT. The solvent was evaporated and the residue was 
extracted with CH2Cl2 several times. The combined organic phases were washed with water 
and dried with Na2SO4, concentrated and then the residue was purified by column 
chromatography, using EtOAc:light petroleum:MeOH (4:4:1)  as eluent to afford compound 
143a (50 mg, 46.2%) as red crystals, mp: 273 oC (decomp.). 
 
1H NMR (500 MHz, CDCl3): δ = 7.48 (m, 1H, H-9), 7.85 (m, 1H, H-10), 8.07 (m, 1H, H-11), 
 9.20 (s,1H, H-4), 9.29 (m, 1H, H-8), 9.46 (s, 1H, H-2). 
13C NMR (125 MHz, CDCl3): δ = 118.2 (C-9), 118.9 (C-11), 123.9 (C-6a), 124.7 (C-
 4a)128.2 (C-8), 132.6 (C-10), 149.0 (C-11a), 149.1 (C12a), 156.0 (C-4), 156.2 (C-
 12b), 161.9 (C-2), 166.7 (C-6), 179.4 (C-5). 
MS m/e (% relative intensity): M+ 250(18.2), 222(100), 194(18.6), 167(43.1), 84 (19.1), 
 78(36.0), 51(37.4). 
IR (KBr disc) υmax: 3123, 3029, 2923, 1709, 1669, 1653, 1646, 1363 cm-1. 
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3. Synthesis of anthrapyrazole derivatives 
 
3.1 Synthesis of 2-(2-(dimethylamino)ethyl)-5-(3-(methylthio)propylamino)indazolo[4,3-
gh] isoquinoline-6(2H)-one (155) 
N
N N
O Cl
S NH2
pyr. 115 oC 30 hr
N
N N
O NH S
NN
153
154
155
 
 
A solution of 3-(methylthio)-propylamine 154 (0.14 g, 1.31 mmol) in absolute 
pyridine (2 mL) was added to a solution of compound 153 (0.1g, 0.30 mmol) in absolute 
pyridine (6 mL). The resulting mixture was then heated to 115 oC under argon atmosphere. 
After 30 h, the solvent was removed in vacuo and the water was added and extracted with 
CH2Cl2 several times. The combined organic phases were washed with water and dried with 
Na2SO4, concentrated and the residue was purified by column chromatography, using 10% 
MeOH/CH2Cl2 as eluent to afford 155 (70 mg, 58.3%) as brown crystals, mp 70-71 oC. 
 
1H NMR (200 MHz, CDCl3): δ = 2.07 (t, 2H, J = 6.8 Hz, CH2SCH3) 2.13 (s, 3H, SCH3),2.31 
 (s, 6H, N(CH3)2), 2.68 (t, 2H, J = 6.9 Hz, CH2CH2N(CH3)2), 2.91 (t, 2H, J = 6.7 Hz, 
 NHCH2),3.60 (m, 2H, NHCH2CH2CH2S), 4.60 (t, 2H, J = 6.8 Hz, CH2CH2N(CH3)2), 
 6.98 (d, 1H, J = 9.2 Hz, H-4), 7.66 (d, 1H, J = 9.2 Hz, H-3), 8.25 (d, 1H, J = 5.2 Hz, 
 H-7) 8.77 (d, 1H, J = 5.3 Hz, H-8), 9.20 (t, 1H, J = 5.4 Hz NH), 9.62 (s, 1H, H-10). 
13C NMR (50MHz, CDCl3): δ = 15.5 (SCH3), 28.5 (CH2SCH3), 31.4 (NHCH2CH2), 41.6 
 (NHCH2), 45.7 (N(CH3)2), 48.8 (CH2CH2N(CH3)2), 59.2 (CH2CH2N(CH3)2), 104.9 
 (C- 5a), 113.3 (C-7), 120.2 (C-4), 120.4 (C-3), 122.8 (C-10c), 125.2 (C-2a), 130.8 (C-
 10b), 134.0 (C-10a), 137.9 (C-5), 145.6 (C-8), 147.6 (C-10), 150.2 (C-6a), 180.8 (C-
 6). 
HRMS (M++1) calculated C21H26ON5S 396.1858, found 396.1847. 
IR (KBr disc) υmax: 3273, 2948, 2921, 2855, 1652, 1604, 1604, 1559 cm-1. 
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3.2 Synthesis of 5-(2-(1H-indol-3-yl)ethylamino)-2-(2-(dimethylamino)ethyl)indazolo 
[4,3-gh]isoquinoline-6(2H)-one (157) 
N
H
NH2
pyr. 115 oC 30 hr
N
N N
O HN
N
N
N N
O Cl
N
N
H
153
156
157
 
 
A solution of tryptamine 156 (0.44 g, 2.74 mmol) in absolute pyridine (2 mL) was 
added to a solution of compound 153 (0.18g, 0.55 mmol) in absolute pyridine (6 mL). The 
resulting mixture was then heated to 115 oC under argon atmosphere. After 30 h, the solvent 
was removed in vacuo and the water was added and extracted with CH2Cl2 several times. The 
combined organic phases were washed with water and dried with Na2SO4, concentrated and 
the residue was purified by column chromatography, using 10% MeOH/CH2Cl2 as eluent to 
afford 157 (0.15 g, 61.5%) as reddish crystals, mp 126-127 oC. 
 
1H NMR (200 MHz, CDCl3): δ = 2.33 (s, 6H, N(CH3)2), 2.90 (t, 2H, J = 6.8 Hz, 
 CH2CH2N(CH3)2), 3.23 (t, 2H, J = 6.7 Hz, CH2-indole), 3.73 (m, 2H, NHCH2), 4.54 
 (t, 2H, J = 6.8 Hz, CH2CH2N(CH3)2), 6.79 (d, 1H, J = 9.2 Hz, H-4), 7.10-7.20 (m, 3H, 
 indole), 7.38 (m, 2H, indole), 7.65 (d, 1H, J = 6.7 Hz, H-3), 8.21 (d, 1H, J = 7.2 Hz, 
 H-7), 8.55 (s, brs, 1H, NH indole), 8.75 (d, 1H, J = 5.3 Hz, H-8), 9.20 (t, 1H, J = 5.2 
 Hz, NHCH2), 9.55 (s, 1H, H-10). 
13C NMR (50 MHz, DMSO-d6): δ = 24.9 (CH2-indole), 43.0 (N(CH3)2), 45.1 (NHCH2),
 47.9(CH2CH2N(CH3)2), 58.8 (CH2CH2N(CH3)2), 103.5 (C-5a), 110.8 (C- indole),      
 111.4 (C- indole), 113.9 (C-7), 118.3 (C-3,C-4), 120.0 (C-indole), 121.0 (C-indole),    
 121.7 (C-10c), 122.0 (C- indole), 123.3 (C- indole),124.6 (C-2a), 127.0 (C- indole), 
 130.7 (C-10b), 132.5 (C-10a), 136.3 (C- indole), 137.2 (C-5), 144.8 (C-8), 147.3 (C-
 10), 149.8 (C-6a), 178.9 (C-6).  
HRMS (M++1) calculated C27H27ON6 451.2246, found 451.2236. 
IR (KBr disc) υmax: 3258, 2922, 2857, 1653, 1603, 1506 cm-1. 
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3.3 Synthesis of 5-(2-(1H-imidazol-4-yl)ethylamino)-2-(2-
(dimethylamino)ethyl)indazolo[4,3-gh]isoquinoline-6(2H)-one (159) 
 
pyr. 115 oC 30 hr
N
N
H
NH2
N
N N
O HN
N
N
H
N
N
N N
O Cl
N
153
158
159
 
 
A solution of histamine 158 (0.21 g, 1.92 mmol) in absolute pyridine (2 mL) was 
added to a solution of compound 153 (0.10 g, 0.30 mmol) in absolute pyridine (6 mL). The 
resulting mixture was then heated to 115 oC under argon atmosphere. After 30 h, the solvent 
was removed in vacuo and the water was added and extracted with CH2Cl2 several times. The 
combined organic phases were washed with water and dried with Na2SO4, concentrated and 
the residue was purified by column chromatography, using 30% MeOH/CH2Cl2 as eluent to 
afford 159 (70 mg, 58.3%) as red crystals, mp 147-148 oC. 
 
1H NMR (200 MHz, CDCl3): δ = 2.28 (s, 6H, N(CH3)2), 2.85 (t, 2H, J = 6.5 Hz,
 CH2CH2N(CH3)2) 3.03 (d, 2H, J = 6.2 Hz, CH2-imidazole), 3.65 (d, 2H, J = 5.8 Hz, 
 NHCH2), 4.45 (t, 2H,  J = 6.5 Hz, CH2CH2N(CH3)2), 6.70 (d, 1H, J = 6.5 Hz, H-4), 
 6.96 (s, 1H, imidazole), 7.37 (d, 1H, J = 9.2 Hz, H-3), 7.61 (s, 1H, imidazole), 8.05 (d, 
 1H, J = 5.2 Hz, H-7), 8.65 (d, 1H, J = 5.3 Hz, H-8), 9.01 (s, 1H, NH), 9.39 (s, 1H, H-
 10). 
13C NMR (50MHz, CDCl3): δ = 29.6 (CH2-imidazole), 43.0 (NHCH2), 45.5 (N(CH3)2), 48.5
 (CH2CH2N(CH3)2), 59.0 (CH2CH2N(CH3)2), 104.5 (C-5a), 113.2 (C-7), 116.2 (C-
 imidazole), 119.9 (C-4), 120.0 (C-3), 122.4 (C-10c), 124.9 (C-2a), 130.5 (C-10b), 
 133.5 (C-10a), 135.2 (C-imidazole), 135.5 (C-imidazole), 137.7 (C-5), 145.2 (C-8), 
 147.2  (C-10), 149.8 (C-6a), 180.0 (C-6). 
HRMS (M++1) calculated C22H22ON7 402.2042, found 402.2025. 
IR (KBr disc) υmax: 3422, 2925, 2864, 2653, 1603, 1560, 1223 cm-1 
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3.4 Synthesis of 2-(2-(dimethylamino)ethyl)-5-(2-(pyridin-2yl)ethylamino)indazolo[4,3-
gh]isoquinoline-6(2H)-one (161) 
N NH2
pyr. 115 oC 30 hr
N
N N
O
N
N
N N
O Cl
N
HN N
153
160
161
 
 
A solution of 2-(2-aminoethyl)pyridine 160 (0.2 mL, 1.67 mmol) in absolute pyridine 
(2 mL) was added to a solution of compound 153 (0.10 g, 0.30 mmol) in absolute pyridine (6 
mL). The resulting mixture was then heated to 115 oC under argon atmosphere. After 30 h, 
the solvent was removed in vacuo and the water was added and extracted with CH2Cl2 
several times. The combined organic phases were washed with water and dried with Na2SO4, 
concentrated and the residue was purified by column chromatography, using 20% 
MeOH/CH2Cl2 as eluent to afford 161 (0.10 g, 47.4%) as reddish oil. 
 
1H NMR (200 MHz, CDCl3): δ = 2.31 (s, 6H, N(CH3)2), 2.92 (t, 2H, J = 6.9 Hz, 
 CH2CH2N(CH3)2), 3.23 (t, 2H, J = 7.0 Hz, CH2-pyridine), 3.92 (m, 2H, NHCH2), 4.61 
 (t, 2H, J = 6.7 Hz, CH2CH2N(CH3)2), 7.03 (d, 1H, J = 9.0 Hz,H-4), 7.13-7.22 (m, 3H, 
 pyridine), 7.59 (dd, 1H, J = 2.0, 7.7 Hz, H-3), 8.26 (d, 1H, J = 5.3 Hz, H-7), 8.60 (d, 
 1H, J = 4.7 Hz, pyridine), 8.76 (d, 1H, J = 5.1 Hz, H-8), 9.31 (t, 1H, J = 5.3 Hz, NH), 
 9.63 (s, 1H, H-10). 
13C NMR (50 MHz, CDCl3): δ = 38.0 (CH2-pyridine), 42.8 (NHCH2), 45.6 (N(CH3)2), 48.8
 (CH2CH2N(CH3)2), 59.1 (CH2CH2N(CH3)2), 105.0 (C-5a), 113.5 (C-7), 120.3 (C-3, 
 C-4), 121.8 (C-pyridine), 122.9 (C-10a), 123.6 (C-pyridine), 125.2 (C-2a), 130.9 (C-
 10b), 134.1 (C-10a), 136.6 (C-pyridine), 138.0 (C-5), 145.6 (C-8), 147.6 (C-10), 
 149.6 (C-pyridine), 150.1 (C-6a), 158.2(C-pyridine), 180.8 (C-6). 
HRMS (M++1) calculated C24H25ON6 413.2090, found 413.2099. 
IR (NaCl disc) υmax: 3289, 3053, 1947, 2854, 2824, 1653, 1607, 1560, 1265, 737 cm-1. 
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3.5 Synthesis of 2-(2-(dimethylamino)ethyl)-5-(2-(1-methylpyrrolidine-2-
yl)ethylamino)indazolo[4,3-gh]isoquinoline-6(2H)-one (163) 
 
N
N N
O HN
N
N
NH2
pyr. 115 oC 30 hr
N
N N
O Cl
N
N
153
162
163
 
 
A solution of 2-(2-aminoethyl)-1-methylpyrrolidine 162 (0.3 mL, 1.31 mmol) in abso-
lute pyridine (2 mL) was added to a solution of compound 153 (0.12 g, 0.37 mmol) in absolu-
te pyridine (6 mL). The resulting mixture was then heated to 115 oC under argon atmosphere. 
After 30 h, the solvent was removed in vacuo and the water was added and extracted with 
CH2Cl2 several times. The combined organic phases were washed with water and dried with 
Na2SO4, concentrated and the residue was purified by column chromatography, using 30% 
MeOH/CH2Cl2 as eluent to provide 163 (0.14 g, 85.8%) as dark oil. 
 
1H NMR (200 MHz, CDCl3): δ = 1.72-1.86 (m, 6H, pyrolidine), 2.31 (s, 3H CH3-pyrolidine), 
 2.35 (s, 6H, N(CH3)2), 2.92 (t, 2H, J = 6.7 Hz, CH2CH2N(CH3)2), 3.08 (m, 1H,
 pyrolidine) 3.52 (m, 4H, NHCH2CH2-pyrolidine), 4.61 (t, 2H, J = 6.7 Hz,
 CH2CH2N(CH3)2), 6.98 (d, 1H, J = 9.2 Hz, H-4), 7.69 (d, 1H, J = 9.1 Hz, H-3), 8.27 
 (d, 1H, J = 5.3 Hz, H-7), 8.78 (d, 1H, J = 9.1 Hz, H-8), 9.23 (s, brs, 1H, NH), 9.64 (s, 
 1H, H-10) 
13C NMR (50 MHz, CDCl3): δ = 22.0 (C-pyrolidine), 30.6 (C-pyrolidine), 33.1 (CH2-
 pyrrolidine), 40.5 (NHCH2), 40.6 (NCH3), 45.7 (N(CH3)2), 48.9 (CH2CH2N(CH3)2 
 57.1 (C- pyrolidine) 59.2 (CH2CH2N(CH3)2), 63.9 (C- pyrolidine), 104.9 (C-5a), 
 113.4 (C-7), 120.3 (C-3), 120.4 (C-4), 122.9 (C-10a), 125.2 (C-2a), 130.8 (C-10b), 
 134.1 (C-10a), 138.0 (C-5), 145.7 (C-8), 147.5 (C-10), 150.2 (C-6a), 180.8 (C-6). 
MS m/e (% relative intensity): M+ 417(1.0), 246(1.0), 320(0.9), 249(1.1), 233(0.9) 111(0.8), 
 97(10.5), 78(36.0), 63(16.0), 51(37.4). 
IR (NaCl disc) υmax: 3282, 3051, 2977, 2780, 1651, 1605, 1504, 1265, 1027 cm-1. 
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3.6 Synthesis of 2-(2-(dimethylamino)ethyl)-5-(2-(thiophen-2-
yl)ethylamino)indazolo[4,3-gh]isoquinoline-6(2H)-one (165) 
 
S
NH2
pyr. 115 oC 30 hr
N
N N
O
N
N
N N
O Cl
N
HN S
153
164
165
 
 
A solution of 2-thiopheneethylamine 164 (0.2 mL, 1.70 mmol) in absolute pyridine (2 
mL) was added into a solution of compound 153 (0.12 g, 0.36 mmol) in absolute pyridine (6 
mL). The resulting mixture was then heated to 115 oC under argon atmosphere. After 30 h, 
the solvent was removed in vacuo and the water was added and extracted with CH2Cl2 
several times. The combined organic phases were washed with water and dried with Na2SO4, 
concentrated and the residue was purified by column chromatography, using 10% 
MeOH/CH2Cl2 as eluent to afford 165 (70 mg, 58.3%) as red oil. 
 
1H NMR (200 MHz, CDCl3): δ = 2.32 (s, 6H, N(CH3)3), 2.92 (t, 2H, J = 6.7 Hz, CH2CH2
 
N(CH3)2), 3.29 (t, 2H, J =7.0 Hz, CH2-thiophene), 3.75 (m, 2H, NHCH2), 4.60 (t, 2H, 
 J = 6.8 Hz, CH2CH2N(CH3)2), 6.97 (m, 3H, H-4, thiophene), 7.18 (m, 1H, H-
 thiophene) 7.67 (d, 1H, J = 9.0 Hz, H-3), 8.26 (d, 1H, J = 5.3 Hz, H-7), 8.77 (d, 1H, J 
 = 5.3 Hz, H-8), 9.27 (t, 1H, J = 5.6 Hz, NH), 9.62 (s, 1H, H-10). 
13C NMR (50MHz, CDCl3): δ = 30.0 (CH2-thiophene), 44.8 (CH2CH2-thiophene), 45.6
 (NH(CH3)2), 48.8  (CH2CH2N(CH3)2), 59.1 (CH2CH2N(CH3)2), 105.0 (C-5a), 113.2   
 (C-7), 120.31 (C-4), 120.35 (C-3), 122.9 (C-10c), 124.1 (C-thiophene), 125.2 (C-2a),
 125.7 (C-thiophene), 127.1(C-thiophene), 30.9(C-10b), 134.1 (C-10a), 137.9 (C-5), 
 140.3 (C-thiophene), 145.6 (C-8), 147.6 (C-10), 149.7 (C-6a), 180.9 (C-6). 
HRMS (M++1) calculated C24H30ON6 418.2481, found 418.1712. 
IR (NaCl disc) υmax: 3286, 3051, 2947, 2860, 2860, 2824, 2775, 1652, 1605, 1568, 1475, 
 1265 cm-1. 
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4. Attempts of a new synthesis of ellipticine (49) 
 
4.1 Synthesis of 4-bromo-2,5-dimethylbezaldehyade (167) 
 
Br
Br
Br
O
1. n-BuLi / THF/ -78 oC
2. DMF rt  1 hr.
             95.8 %
166
167
 
 
 To a solution of 1,4-dibromo-2,5-dimethylbenzene 166 (5.28g, 20 mmol) in 
anhydrous THF (3 mL) n-BuLi (14 mL, 22 mmol, 1.6 M in hexane) was slowly added 
dropwise at -78 oC for 30 min. After 30 min N,N-dimethylformamide (3 mL, 40 mmol) was 
added, then the resulting mixture was warmed to RT and continuously stirred for 1 h. 
Saturated NH4Cl (30 mL) was added. The aqueous phase was extracted with ether (2x100 
mL). The organic layer was washed with brine (100 mL), dried with Na2SO4 and 
concentrated in vacuo to obtain the pure product (4.05 g, 95.8%) as a white solid, mp 57-59 
oC. The fully characterization of compound 167 is in reference [64]. 
 
1H NMR (200 MHz, CDCl3): δ = 2.31 (s, 3H), 2.48 (s, 3H), 7.34 (s, 1H), 7.50 (s, 1H), 10.0 
 (s, 1H). 
13C NMR (50MHz, CDCl3): δ = 18.5, 22.1, 131.2, 132.9, 133.5, 135.3, 136.0, 139.2, 191.7. 
 
4.2 Synthesis of N-(4-bromo-2,5-dimethylbenzulidene)diethhoxymethanamine (143) 
 
168167
Br
O
O O
160 oC, 90 min
84.4%
Br
N
NH2
O
O
 
 
 A mixture of 4-bromo-2,5-dimethylbezaldehyde 167 (0.5 g, 2.37 mmol) and 
aminoacetaldehyde diethyl acetal (0.7 mL, 4.78 mmol) was refluxed at 160 oC. After 90 min, 
  
 
 
105
the reaction mixture was allowed to cool and the resulting liquid was removed and the 
distillation of the remaining acetal in vacuo to give the acetal 168 (0.681 g, 87.61%) as beige 
oil.      
 
1H NMR (200 MHz, CDCl3): δ = 1.19 (t, 6H, J = 7.0 Hz), 2.35 (s, 3H), 2.41 (s, 3H), 3.55 (dd, 
 2H, J = 2.2, 7.0 Hz), 3.68 (dd, 2H, J = 2.3, 7.0 Hz), 3.76 (d, 2H, J =2.0 Hz), 4.79 (t, 
 1H, J = 2.0 Hz), 7.35 (s, 1H), 7.71 (s, 1H), 8.48 (s, 1H). 
13C NMR (50MHz, CDCl3): δ = 15.3, 18.2, 22.1, 62.2, 64.9, 101.9, 127.1, 129.1, 133.1, 
 134.2,  135.5, 136.5, 161.3. 
MS m/e (% relative intensity): M+ 327(0.5), 264(40.0), 183(31.8), 103(100.0), 75(58.6), 47
 (88.9). 
IR (KBr disc) υmax: 2974, 2925, 2881, 1648, 1598, 1481, 1443, 1129, 1068, 967 cm-1 
 
4.3 Synthesis of 7-bromo-5,8-dimethylisoquinoline (169) 
 
168
Br
NH2SO4/ P2O5
160 oC, 45 min
17.2%
Br
N
O
O
169
 
 
A mixture of P2O5 (35.6 g) and conc. H2SO4 (150 mL) was heated in a 160 oC oil 
bath. N-(4-bromo-2,5-dimethylbenzylidene)diethoxymethanamine 168 (8.41 g, 25.7 mmol) 
was dissolved in  conc. H2SO4 (50 mL) and then the resulting solution was added rapidly to 
the reaction mixture. The mixture was allowed to react for 45 min. After that the mixture was 
cooled to RT, poured into ice (1 L) and basified using Na2CO3. The mixture was extracted 
with CH2Cl2 several times. The organic layer was dried with Na2SO4 and evaporated to give a 
brown residue. Chromatography on silica gel (40%EtOAc in petroleumether) gave 1.04 g 
(17.2%) of product as a yellowless solid, mp 102-103 oC. The fully characterization of 
compound 169 is in reference [64]. 
 
1H NMR (200 MHz, CDCl3): δ = 2.70 (s, 6H), 7.74 (s, 1H), 7.75 (d, 1H, J = 5.9 Hz), 8.60 (d, 
 1H, J = 5.9 Hz), 9.37 (s, 1H). 
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13C NMR (50MHz, CDCl3): δ = 17.9, 117.3, 126.6, 126.9, 130.7, 131.9, 134.6, 136.2, 143.8, 
 149.7. 
 
4.4 Synthesis of N-(2-chlorophenyl)-2,5-dimethyl-6-isoquinoline (170) 
170
169
N
H
N
9.6%
Br
N
Cl
N
H
N
Pd(PAc)2 / NaO
tBu
[BF4][HP
tBu3]
toluene/DMF 160 oC
90 min
2-chloroaniline
14.3%
+
171
 
 
 NaOtBu (91 mg, 0.94 mmol), Pd(OAc)2 (7 mg, 0.03 mmol), and [BF4][HPtBu3] (14 
mg, 0.05 mmol) were suspended in toluene (9 mL) and DMF (3 mL). 2-Chloroaniline (0.05 
mL, 1.0 mmol) and 7-bromo-2,5-dimethylisoquinoline 169 (109 mg, 0.46 mmol) were added, 
and the microwave tube was sealed. The reaction mixture was heated in a microwave reactor 
at 160 oC for 90 min. After that, the mixture was cooled to RT and quenched by addition with 
2 N HCl (2x20 mL). The organic layer was extracted with CH2Cl2 (3x100 mL) and dried over 
Na2SO4. The solvent was removed under reduced pressure to give crude product, purified by 
chromatography (40% light petroleum in EtOAc) to give 170 (34 mg, 11.0 %) as yellow crys-
tals, mp 140-142 oC and 171 (20 mg, 9.6%) as yellow crystal, mp 172-173 oC. 
 
170: 
1H NMR (200 MHz, CDCl3): δ = 2.37 (s, 3H), 2.63 (s, 3H), 6.81 (dd, 1H, J = 1.4, 8.1 Hz), 
 6.93 (dt, 1H, J = 1.4, 8.0 Hz), 7.07 (s, 1H), 7.18 (dt, 1H, J = 1.4, 8.0 Hz), 7.45 (dd, 1H, 
 J = 1.4, 8.0 Hz), 7.59 (s, 1H), 7.79 (d, 1H, J = 6.0 Hz), 8.46 (d, 1H, J = 6.0 Hz), 9.27 
 (s, 1H). 
13C NMR (CDCl3, 50 MHz) δ = 12.3, 18.0, 116.8, 118.9, 122.0, 123.40, 123.43, 124.1, 127.9, 
 129.9, 133.8, 136.5, 140.8, 141.6, 143.1, 149.0. 
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MS m/e (% relative intensity): M+ 282(28.0), 247(87.2), 232(76.1), 171(34.8), 144(25.8), 
 127(43.8), 115(53.1), 102(57.7), 75(62.0), 44(100). 
IR (KBr disc) υmax: 3238, 3063, 2964, 1612, 1588, 1466, 1292, 1032, 738 cm-1. 
 
4.5 Synthesis of 5,8-dimethyl-N-phenyl-6-isoquinoliamine (171) 
 
170 171
N
H
N
Pd(PAc)2 / NaO
tBu
[BF4][HP
tBu3]
toluene/DMF 160 oC
90 min
60.0 %
Cl
N
H
N
 
 
 NaOtBu (27.0 mg, 0.283 mmol), Pd(OAc)2 (1.5 mg, 0.007 mmol), and [BF4][HPtBu3] 
(3.3 mg, 0.0014 mmol) were suspend in toluene (9 mL) and DMF (3 mL). N-(2-
Chlorophenyl)-2,5-dimethyl-6-isoquinoline 170 was then added, and the microwave tube was 
sealed. The reaction mixture was heated in microwave reactor at 160 oC for 90 min. After 
that, the mixture was cooled to RT and quenched by addition of 2 N HCl (2x5 mL). The 
organic layer was extracted with CH2Cl2 (3x30 mL) and dried with Na2SO4. The solvent was 
removed under reduced pressure to give crude product, purified by chromatography (40% 
light petroleum in EtOAc) to yield 171 (21 mg, 60.0 %), mp 172-173 oC. 
 
1H NMR (200 MHz, CDCl3): δ = 2.45 (s, 3H), 2.67 (s, 3H), 5.90 (s, 1H), 7.01 (m, 1), 7.04 
 (m, 2H), 7.32 (m, 2H), 7.69 (dd, 1H, J = 6.0 Hz), 8.48 (d, 1H, J = 6.0 Hz), 9.27 (d, 1H, 
 J = 0.9 Hz). 
13C NMR (CDCl3, 50 MHz) δ = 11.7, 18.5, 115.7, 116.5, 118.7, 120.9, 121.8, 124.2, 129.4
 134.3, 137.1, 142.7, 141.8, 143.1, 149.1. 
MS m/e (% relative intensity): M+ 248(100), 233(17.6), 171(27.9), 116(47.2), 102(21.3), 
 51(17.9). 
IR (KBr disc) υmax:  3246, 3069, 2919, 1614, 1593, 1342, 1280, 1033, 808, 700 cm-1. 
 
 
 
 
 
  
 
 
108
4.6 Synthesis of 5,8-dimethyl-N-phenyl-6-isoquinolinamine (171) 
 
 
 
 
 
 
 
NaOtBu (0.4 g, 4.2 mmol), Pd(OAc)2 (24 mg, 0.01 mmol), and [BF4][HPtBu3] (62 
mg, 0.2 mmol) were suspend in DMA (12 mL). Aniline (0.20 mL, 2.1 mmol) and 7-bromo-
2,5-dimethylisoquinoline 169 (0.5 g, 2.1 mmol) were then added, and the microwave tube 
was sealed. The reaction mixture was heated in microwave reactor at 160 oC for 45 min. Af-
ter that, the mixture was cooled to RT and quenched by addition of 2 N HCl (2x20 mL). The 
organic layer was extracted with CH2Cl2 (3x75 mL) and dried over Na2SO4. The solvent was 
removed under reduced pressure to give crude product, purified by column chromatography 
(40% light petroleum in EtOAc) to yield 171 (0.25 g, 42.0 %), mp 172-173 oC. 
 
1H NMR (200 MHz, CDCl3): δ = 2.45 (s, 3H), 2.67 (s, 3H), 5.90 (s, 1H), 7.01 (m, 1), 7.04 
 (m, 2H), 7.32 (m, 2H), 7.69 (dd, 1H, J = 6.0 Hz), 8.48 (d, 1H, J = 6.0 Hz), 9.27 (d, 1H,  
 J = 0.9 Hz). 
13C NMR (CDCl3, 50 MHz) δ = 11.7, 18.5, 115.7, 116.5, 118.7, 120.9, 121.8, 124.2, 129.4
 134.3, 137.1, 142.7, 141.8, 143.1, 149.1. 
MS m/e (% relative intensity): M+ 248(100), 233(17.6), 171(27.9), 116(47.2), 102(21.3), 
 51(17.9). 
IR (KBr disc) υmax:  3246, 3069, 2919, 1614, 1593, 1342, 1280, 1033, 808, 700 cm-1. 
 
 
 
 
 
 
 
 
1 6 9 1 7 1
N
H
N
Pd(PAc)2 / NaO
tBu
[BF4][HP
tBu3]
toluene/DMF 200 oC
40 min
42.0 %
Br
N aniline
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IR spectrum of 103 (NaCl). 
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Mass spectrum of 103. 
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1H NMR spectrum of 103 in CDCl3. 
4
.
0
2
7
9
5
.
9
1
6
7
2
.
0
0
8
4
2
.
0
0
5
5
3
.
9
8
9
0
0
.
9
5
5
4
9
.
0
0
0
0
I
n
t
e
g
r
a
l
7
.
7
1
3
8
7
.
7
0
5
6
7
.
6
9
4
2
7
.
6
7
9
7
7
.
6
6
7
7
7
.
4
5
0
0
7
.
4
2
5
4
7
.
3
9
2
5
7
.
3
6
6
0
3
.
8
4
2
3
3
.
8
0
8
2
3
.
7
7
4
1
3
.
6
3
3
3
2
.
7
0
3
6
2
.
6
8
2
2
2
.
6
6
9
6
2
.
6
5
3
1
2
.
6
3
5
5
2
.
6
2
4
1
1
.
0
7
0
2
( p p m)
0 . 00 . 51 . 01 . 52 . 02 . 53 . 03 . 54 . 04 . 55 . 05 . 56 . 06 . 57 . 07 . 58 . 0
 
S
O
Si
Ph
Ph
HO
103
  
 
 
4
13C NMR spectrum of 103 in CDCl3. 
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IR spectrum of 104 (NaCl). 
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Mass spectrum of 104. 
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1H NMR spectrum of 104 in CDCl3. 
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13C NMR spectrum of 104 in CDCl3. 
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IR spectrum of 106 (KBr). 
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Mass spectrum of 106. 
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1H NMR spectrum of 106 in CDCl3. 
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13C NMR spectrum of 106 in CDCl3. 
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IR spectrum of 107 (KBr). 
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Mass spectrum of 107. 
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1H NMR spectrum of 107 in DMSO-d6. 
1
.
0
0
0
0
1
.
0
0
0
5
1
.
0
1
2
8
2
.
0
2
7
2
2
.
0
3
9
0
1
.
9
8
1
2
1
.
2
7
3
1
2
.
0
0
7
0
2
.
0
1
9
2
1
.
9
7
9
2
I
n
t
e
g
r
a
l
9
.
1
9
2
9
9
.
1
7
4
0
9
.
0
3
5
2
8
.
1
8
1
2
7
.
8
5
1
7
7
.
5
0
9
6
7
.
4
7
6
8
7
.
4
4
4
0
7
.
4
0
5
5
4
.
8
4
6
1
4
.
8
2
3
4
4
.
6
5
8
7
3
.
5
8
5
1
3
.
5
5
2
2
3
.
5
1
9
4
2
.
9
5
3
3
2
.
7
0
2
7
2
.
6
6
9
9
2
.
6
3
7
7
( p p m)
0 . 51 . 01 . 52 . 02 . 53 . 03 . 54 . 04 . 55 . 05 . 56 . 06 . 57 . 07 . 58 . 08 . 59 . 09 . 5
  a l c o h o l - s u l f i d e P R OT ON  DM S O o p t / x w i n n mr  l e e p a s e r t  3 3
 
 
O
N
N
O
S
OH
107
  
 
 
16
13C NMR spectrum of 107 in DMSO-d6. 
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IR spectrum of 108 (KBr). 
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Mass spectrum of 108. 
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1H NMR spectrum of 108 in DMSO-d6. 
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13C NMR spectrum of 108 in DMSO-d6. 
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IR spectrum of 109 (KBr). 
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Mass spectrum of 109. 
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1H NMR spectrum of 109 in CDCl3. 
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13C NMR spectrum of 109 in CDCl3. 
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1H NMR spectrum of 112 in CDCl3. 
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1H NMR spectrum of 113 in CDCl3. 
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IR spectrum of 114 (KBr). 
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Mass spectrum of 114. 
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1H NMR spectrum of 114 in CDCl3. 
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13C NMR spectrum of 114 in CDCl3. 
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IR spectrum of 116 (KBr). 
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Mass spectrum of 116. 
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1H NMR of spectrum of 116 in DMSO-d6. 
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13C NMR of spectrum of 116 in DMSO-d6. 
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IR spectrum of 117 (KBr). 
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Mass spectrum of 117. 
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1H NMR of spectrum of 117 in DMSO-d6 
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13C NMR of spectrum of 117 in DMSO-d6. 
1
7
9
.
3
3
6
8
1
7
7
.
6
3
5
3
1
5
5
.
7
7
7
4
1
4
7
.
4
8
0
7
1
3
8
.
8
0
5
9
1
3
8
.
7
1
8
6
1
3
4
.
3
3
3
9
1
2
7
.
6
2
2
4
1
2
6
.
2
4
0
8
1
2
5
.
1
1
3
8
1
2
2
.
8
0
1
5
1
2
2
.
4
1
6
1
1
1
8
.
3
0
0
4
1
1
8
.
1
2
5
9
1
1
2
.
6
5
0
6
4
6
.
4
0
0
6
2
.
5
0
3
0
( p p m)
02 04 06 08 01 0 01 2 01 4 01 6 01 8 02 0 0
 
N N
O
O
I 117
  
 
 
39
IR spectrum of 119 (KBr). 
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Mass spectrum of 119. 
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1H NMR spectrum of 119 in CDCl3. 
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13C NMR spectrum of 1 in CDCl3. 
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NOESY spectrum of 119. 
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COSY spectrum of 119. 
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IR spectrum of 120 (KBr). 
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Mass spectrum of 120. 
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1H NMR spectrum of 120 in CDCl3. 
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13C NMR spectrum of 120 in CDCl3. 
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IR spectrum of 122 (NaCl). 
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Mass spectrum of 122. 
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1H NMR spectrum of 122 in CDCl3. 
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13C NMR spectrum of 122 in CDCl3. 
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IR spectrum of 123 (KBr). 
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Mass spectrum of 123. 
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1H NMR spectrum of 123 in CDCl3. 
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13C NMR spectrum of 123 in CDCl3. 
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IR spectrum of 124 (KBr). 
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Mass spectrum of 124. 
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1H NMR spectrum of 124 in CDCl3. 
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13C NMR spectrum of 124 in CDCl3. 
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IR spectrum of 128a (KBr). 
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Mass spectrum of 128a. 
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1H NMR of spectrum of 128a in DMSO-d6. 
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13C NMR of spectrum of 128a in DMSO-d6. 
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HMBC spectrum of 128a. 
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IR spectrum of 128b (KBr). 
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Mass spectrum of 128b. 
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1H NMR of spectrum of 128b in DMSO-d6. 
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13C NMR of spectrum of 128b in DMSO-d6. 
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HSQC spectrum of 128b. 
 
 
N
O
O
N
N
Cl
128b
  
 
 
72
IR spectrum of 134a (KBr). 
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Mass spectrum of 134a. 
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1H NMR of spectrum of 134a in DMSO-d6. 
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13C NMR of spectrum of 134a in DMSO-d6. 
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HSQC spectrum of 134a. 
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IR spectrum of 134b (KBr). 
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Mass spectrum of 134b. 
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1H NMR of spectrum of 134b in DMSO-d6. 
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13C NMR of spectrum of 134b in DMSO-d6. 
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HSQC spectrum of 134b. 
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COSY spectrum of 134b. 
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IR spectrum of 136a (KBr). 
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Mass spectrum 136a. 
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1H NMR of spectrum of 136a in DMSO-d6. 
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13C NMR of spectrum of 136a in DMSO-d6. 
 
 
 
N
O
O
N
N
NO2136a
  
 
 
87
HMQC spectrum of 136a. 
 
 
 
 
 
 
N
O
O
N
N
NO2136a
  
 
 
88
IR spectrum of 138b (KBr). 
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Mass spectrum of 138b. 
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1H NMR spectrum of 138b in CDCl3. 
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13C NMR spectrum of 138b in CDCl3. 
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HMQC spectrum of 138b. 
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IR spectrum of 143a (KBr). 
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Mass spectrum of 143a. 
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1H NMR of spectrum of 143a in DMSO-d6. 
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13C NMR of spectrum of 143a in DMSO-d6. 
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HMQC spectrum of 143a. 
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IR spectrum of 155 (KBr). 
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Mass spectrum of 155. 
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1H NMR spectrum of 155 in CDCl3. 
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13C NMR spectrum of 155 in CDCl3. 
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IR spectrum of 157 (KBr). 
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Mass spectrum of 157. 
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1H NMR spectrum of 157 in DMSO-d6. 
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.
13C NMR of spectrum of 157 in DMSO-d6. 
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IR spectrum of 159 (KBr). 
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Mass spectrum of 159. 
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1H NMR of spectrum of 159 in DMSO-d6. 
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13C NMR of spectrum of 159 in DMSO-d6. 
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IR spectrum of 161 (NaCl). 
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Mass spectrum of 161. 
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1H NMR spectrum of 161 in CDCl3. 
 
1
.
0
0
0
0
0
.
8
1
9
5
1
.
1
4
3
6
0
.
9
9
2
1
1
.
0
6
4
6
1
.
3
5
4
9
1
.
0
1
3
8
0
.
8
0
1
9
0
.
8
5
1
8
1
.
0
6
4
6
2
.
0
5
2
5
2
.
0
2
4
9
2
.
2
0
3
2
2
.
1
6
2
0
5
.
8
4
5
1
I
n
t
e
g
r
a
l
9
.
6
3
3
2
9
.
3
4
4
7
9
.
3
1
7
6
9
.
2
9
1
1
8
.
7
8
3
6
8
.
7
5
7
7
8
.
6
1
8
9
8
.
5
9
5
5
8
.
2
8
1
2
8
.
2
5
4
7
7
.
6
9
8
0
7
.
6
5
2
0
7
.
6
2
1
7
7
.
6
1
4
1
7
.
5
8
3
8
7
.
5
7
4
9
7
.
2
2
0
9
7
.
2
0
1
3
7
.
1
7
4
8
7
.
1
6
4
7
7
.
1
3
9
4
7
.
0
5
8
0
7
.
0
1
2
6
4
.
6
4
7
6
4
.
6
1
4
2
4
.
5
9
5
2
4
.
5
8
0
7
3
.
9
7
6
1
3
.
9
4
2
0
3
.
9
1
0
4
3
.
8
7
5
7
3
.
4
7
6
8
3
.
2
7
2
9
3
.
2
3
7
6
3
.
2
0
2
3
2
.
9
6
1
2
2
.
9
2
7
7
2
.
8
9
4
3
2
.
3
1
9
9
( p p m)
0 . 01 . 02 . 03 . 04 . 05 . 06 . 07 . 08 . 09 . 01 0 . 0
 
 
N
N N
O
N
HN N
161
  
 
 
113
13C NMR spectrum of 161 in CDCl3. 
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IR spectrum of 163 (NaCl). 
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Mass spectrum of 163. 
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1H NMR spectrum of 163 in CDCl3. 
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13C NMR spectrum of 163 in CDCl3. 
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IR spectrum of 165 (NaCl). 
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Mass spectrum of 165. 
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1H NMR spectrum of 165 in CDCl3. 
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13C NMR spectrum of 165 in CDCl3. 
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1H NMR spectrum of 167 in CDCl3 
. 
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IR spectrum of 168 (NaCl). 
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Mass spectrum of 168. 
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1H NMR spectrum of 168 in CDCl3. 
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13C NMR spectrum of 168 in CDCl3. 
1
6
1
.
2
9
7
7
1
3
6
.
5
8
2
1
1
3
5
.
5
8
5
9
1
3
4
.
2
0
4
3
1
3
3
.
1
3
5
4
1
2
9
.
1
3
6
1
1
2
7
.
1
2
2
0
1
0
1
.
9
3
3
7
6
4
.
9
0
7
6
6
2
.
6
4
6
2
2
2
.
1
8
0
7
1
8
.
2
4
6
8
1
5
.
3
0
9
2
( p p m)
- 1 001 02 03 04 05 06 07 08 09 01 0 01 1 01 2 01 3 01 4 01 5 01 6 01 7 0
 
168
Br
N
O
O
  
 
 
127
1H NMR spectrum of 169 in CDCl3. 
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13C NMR spectrum of 169 in CDCl3. 
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IR spectrum of 170 (KBr). 
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Mass spectrum of 170. 
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1H NMR of spectrum of 170 in DMSO-d6. 
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13C NMR of spectrum of 170 in DMSO-d6. 
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IR spectrum of 171 (KBr). 
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Mass spectrum of 171. 
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1H NMR spectrum of 171 in CDCl3. 
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13C NMR spectrum of 171 in CDCl3. 
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